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1 Introduction 
Patient safety and effective disease management are major aspects 
of healthcare strategies. Consequently, over the last two decades there has 
been an increase in communication between clinical diagnostic laboratories 
and clinical decision makers as to what would be the optimum therapeutic 
agent to use. The two main arms of medicine and, by extension also 
personalized medicine, are laboratory based tests and the choice of suitable 
treatments. 
 The early detection of nucleic acids of different natures (such as 
DNA, RNA and miR) obtained from different sources such as serum, plasma, 
infectious diseases (e.g. viral and bacterial), and cells is typically crucial for 
successful patient management. Consequently, clinical laboratory medicine 
strives for the development of molecular assays with high sensitivity, 
specificity, and multiplexing capabilities, with short turnaround times and 
lower costs. Despite the recent progress in this, some major challenges 
remain. These still include the rapid delivery of results within 24 hours, 
which is especially essential in hospitals and in particular their intensive care 
units. In addition, some types of analysis deal with very small sample 
quantities/volumes, as occurs often in forensic medicine laboratories and 
neonatal screening units. Furthermore, there is often a narrow 
concentration range of the analytes between healthy and the diseased 
states, and detection methods inevitably require the dilution of samples that 
are only available in small volumes (Schleicher 2006).Currently used 
techniques, such as DNA microarrays, real-time and conventional PCR, and 
branched DNA assay, requires multistep procedures that are time-
consuming, labor-intensive, expensive, and sophisticated equipment.  
Several criteria, such as specificity, sensitivity, reproducibility, simplicity and 
cost, should be taken into consideration for the development of new and 
optimized molecular assays. These challenges drive a constant search for 
alternative and improved assays, and have triggered the introduction of 
novel and often innovative approaches and technologies. Nanotechnology is 
one of those approaches. 
Nanotechnology is the creation and utilization of materials, devices, 
and systems on the nanometer-length scale (10-9meter) (Hood 2004, Jain 
2005) that can be applied to molecular diagnostics, with the overall outcome 
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leading to an enhancement in clinical health care, and patient safety. The 
use of materials and chemicals at the nano-scale dimensions allows the 
utilization of unique properties that are not observed in bulk form, and 
include new colors and electronic, magnetic and mechanical properties. 
These depend on the type of the particle used, i.e. at nano-scale dimensions 
there is ideally an enhancement in the physical and chemical properties of 
the materials used. The blooming field of nanotechnology has generated 
several nanostructures with remarkable diagnostic applications over the 
past few years, which will almost inevitably propel clinical diagnostics to new 
frontiers. An assortment of nanoparticles, of various sizes, shapes, 
compositions, chemical and surface properties, and functionalized with 
various ligands (such as oligonucleotides, antibodies, cross linkers, 
polymers), has already been constructed. The evolving use of nanoparticles 
in diagnostic applications shows great promise to meet the rigorous 
demands of the clinical laboratory mainly in regard to sensitivity, specificity 
and cost-effectiveness (Azzazy et al. 2006). The unique optical and physical 
properties of nanoparticles and their extremely small size allows them to 
interact with bio-molecules and cellular structures, on a one-to-one level. 
This enables obtaining information on the single molecule level rather than 
data averaged over an ensemble of molecules, thereby leading to great 
assay sensitivity. The utility of nanoparticles would result in efficient, 
accurate, cost-effective diagnostic assays and would aid the development of 
point-of-care test, in line with the wanted paradigm shift of clinical 
laboratory medicine. 
The most promising nanoparticles that may have a positive influence 
on clinical diagnostics are gold, iron oxide nanoparticles and quantum dots, 
due to their unique optical, magnetic and fluorescent properties 
respectively. My PhD research is focused on the magnetic and gold 
nanoparticles (AuNPs) and their role in the purification and detection of 
various nucleic acids. 
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Gold nanoparticles (AuNPs) 
Structure and physical properties of gold nanoparticles  
AuNPs are typical, solid spherical particles having either a negative 
or positive charge. Other shapes can also be synthesized, e.g. prisms, rods 
or a thin gold shell surrounding a dielectric core (an insulating material such 
as silica) and each with dimensions ranging from 0.8-250 nm (Liu 2006). 
AuNPs have found their way into clinical diagnostics due to their 
unique optical properties. They have large molar extinction coefficients 
(>108 M-1 cm-1) (Xie 2004). AuNPs exhibit a unique feature known as Surface 
Plasmon Resonance (SPR), which is responsible for the large absorption and 
cross-sectional scattering of AuNPs. These properties are about five orders 
of magnitude greater than that of conventional organic dyes (Huang et al. 
2007). SPR is due to the collective resonant oscillations of free electrons at 
the surface of nanoparticles, which is induced by the alternating 
electromagnetic field of the incoming light, which has a wavelength greater 
than the AuNPs’ diameter. This gives rise to intense colors for those particles 
within the visible frequencies, and is responsible for the strong optical and 
scattering properties of the AuNPs (Figure 1.1).  
Figure 1.1: The surface Plasmon Resonance of AuNPs. Collective dipolar oscillations of the 
AuNPs surface electrons are induced by the oscillating electric field of the light. 
AuNPs’ high absorption coefficient is determined by the size and 
shape of the particles. The variation in relative thickness of the core and 
outer shell allows changes in the optical resonance of gold, shifting it as far 
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as the mid-infrared region (West et al. 2003, Rosi et al. 2005, Baptista et al. 
2007). These optical properties are indeed influenced by the particle size and 
shape, but also by the dielectric constant of the medium and by the 
temperature (Daniel et al. 2004), which gives gold nanoparticles the 
advantages of multi-color tracking for assays using one light source, without 
any need for filters (Liu et al. 2007).  
However, with gold nanoparticles smaller than 2 nm in diameter, the 
SPR disappears or decreases due to surface scattering of the conducting 
electrons, which decreases the intensity of the SPR as particle size decreases 
and is accompanied by broadening of the Plasmon bandwidth (Haiss et al. 
2007). SPR however, increases with decreasing size when the particle 
diameter is smaller than 25 nm, and increases with increasing size when the 
particle diameter is larger than 25 nm (Daniel et al. 2004). A closely related 
process, called plasmon-plasmon interaction, allows the use of gold 
nanoparticles as labels for the colorimetric detection of biomolecules. 
Colloidal solutions of negatively charged, aggregated AuNPs are mainly 
achieved using sodium chloride salt as salt, a process also known as salt-
induced aggregation (Baptista et al. 2008). When nanoparticles aggregate, 
the interaction of locally adjacent AuNPs (plasmon-plasmon interaction) 
shifts the color of a colloidal solution of spherical AuNPs from red to blue. 
Thus, the binding of labeled entities to their respective target could lead to 
aggregation of the nanoparticles and a detectable shift in the optical signal 
(West et al. 2003, Azzazy et al. 2006, Baptista et al. 2007, Jain et al. 2007). 
Additionally, the SPR of AuNPs shifts to higher wavelengths with an increase 
in the refractive index of the medium (Lucia 2006). Thus, this would allow 
the detection of the binding or adsorption of AuNPs to surfaces or targets 
(Jain et al. 2007). Most importantly in clinical applications is that different 
biological molecules, such as peptides, proteins, DNA and polymers (Daniel 
et al. 2004), could be conjugated easily to the surface of AuNPs, where their 
number as well as conformation could be easily controlled (Kenji Suzuki 
2009). Moreover, AuNPs exhibit good conductivity of electrical and thermal 
energy. Owing to the aforementioned properties AuNPs have indeed 
meanwhile found their way into nucleic acid detection. 
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 Synthesis of gold nanoparticles 
Several methods have been established for preparing colloidal 
solutions of gold nanoparticles, either chemically or physically, and different 
shapes, sizes and charges have been produced (Daniel et al. 2004, Cheng et 
al. 2006, Radha Narayanan 2008). Preparation of gold nanoparticles is 
dependent mainly on the reduction of gold (III) ions, as chloroaurate, into 
metallic gold using a reducing agent; the latter is generally the capping agent 
that coats the formed metallic gold. The particle diameter is usually 
controlled by varying the reducing/capping agent concentration (Jana et al. 
2001, Rao Cn et al. 2004).Reduction of gold ions has been chemically 
achieved using several reducing agents, such as sodium borohydride, 
phosphonium chloride and sodium citrate (Frens 1973, Duff et al. 1993, 
Brust et al. 1994). Also, AuNPs have been synthesized by more ecologically 
sustainable methods using bacteria, fungi, and plant extracts (Shiying He et 
al. 2007, Bhambure et al. 2009, Castro L et al. 2010). In addition, the Brust-
Schiffrin and seeding growth methods, respectively are two common 
techniques used in AuNPs synthesis (Jana et al. 2001, Daniel et al. 2004).The 
Brust-Schiffrin method was first published in 1995 (Brust et al. 1995). This 
method resulted in thermally and air stable AuNPs with a narrow size 
distribution ranging from 1.5 to 5.2 nm in diameter. These AuNPs could be 
easily isolated, re-dissolved in organic solvents, and made to function 
without aggregation or decomposition. They were obtained by reduction of 
gold (III) ions by an aqueous solution of sodium borohydride in the presence 
of dodecanethiol. This reduction step is done after transferring the gold ion 
precursors to toluene using tetra-octyl-ammonium bromide. As a result, the 
organic phase changes its color from orange to deep brown upon reduction 
by the borohydride. Brust and co-workers then succeeded in synthesizing 
AuNPs stabilized by p-mercaptophenol in one single step, thereby opening a 
path for the production of AuNPs stabilized by a variety of functional thiol 
ligands (Chen et al. 1998, Chen 1999). The size of the particles is controlled 
by adjusting the number of thiols to the gold ions in the reaction (Daniel et 
al. 2004, Zhenxin Wang et al. 2009). The most popular and simple method 
used for preparing gold nanoparticles is the citrate reduction method. 
Preparation of colloidal gold nanoparticles of 20 nm was first introduced and 
proposed by (Turkevich et al. 1951), and further developed by Frens (Frens 
1973). As a result, a controlled particle size, ranging from 16 and 147 nm, 
was obtained. The mechanism of the citrate reduction of gold (III) ions into 
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gold nanoparticles is meanwhile fully understood (Turkevich 1985b, 
Turkevich 1985a). Synthesis of AuNPs by citrate reduction method is 
performed by the rapid addition of tri-sodium citrate to a boiling yellow 
solution of chlorauric acid. This changes the color of the solution from yellow 
over white to deep red within seconds, which indicates the formation of the 
AuNPs. The roles of citrate in the reaction are to serve as a reducing agent 
for the gold chloride and cap the produced nanoparticles. The citrate in the 
reaction is oxidized and reduces the gold ions to gold atoms. Nucleation 
occurs on the formed gold atoms, followed by growth of the nanoparticles 
capped with citrate ions, yielding an overall negative charge of the AuNPs. 
The difference in concentrations of the citrate and the gold ions, in addition 
to other reaction parameters such as temperature and pH, controls the size 
of the particles that are formed; the larger the citrate to gold ion ratio, the 
smaller the particles will be (Storhoff et al. 1998, Daniel et al. 2004, Kimling 
et al. 2006). The seeding growth method is another common technique for 
synthesizing AuNPs and to control their size distribution, and is used 
especially when large particles are needed (Belloni 1996, Brown et al. 1998, 
Jana et al. 2001, Perrault et al. 2009). The method is usually performed by 
firstly preparing the seed solution by reducing the gold ions with a reducing 
agent such as citrate or sodium borohydride (similar as above). As a result, 
small mono-disperse particles are produced that are then used as seeds for 
producing larger particles by adding them to a solution in which gold ions 
were previously reduced to metallic gold by a weak reducing agent, such as 
ascorbic acid or hydroquinone. The particle size is controlled by the amount 
of the seed nanoparticles added. Moreover, the shape and size of the AuNPs 
can be controlled in this seeding growth procedures by adding a surfactant, 
such as cetyl-tri-methyl-ammonium bromide (CTAB) and/or benzyl-
dimethyl-hexa-decyl-ammonium chloride (BDAC), and silver nitrate. This has 
for example been used in the synthesis of gold nanorods with different 
aspect ratios, primarily by changing the concentrations of the surfactants 
(micelle formed) and silver nitrate, and was also used to produce positively 
charged gold nanoparticles (Carrot et al. 1998, Nikoobakht et al. 2001, 
Murphy et al. 2002, Busbee et al. 2003, Huang et al. 2007).  
There are many methods for characterizing the produced AuNPs, 
such as Transmission Electron Microscopy (TEM), Scanning Electron 
Microscopy (SEM), and Atomic Force Microscopy (AFM) (Daniel et al. 2004, 
Sun et al. 2009). All are used for the size and morphology determination of 
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the nanoparticles. Also, the conventional UV/visible spectrophotometer is 
still commonly used for estimating particle size [according to the extinction 
coefficients of the nanoparticles (Liu et al. 2007)], and the particle 
concentration [from the intensity of the surface Plasmon band of the 
colloidal solution according to Beer-Lambert law (Jain et al. 2006, Haiss et al. 
2007)]. As mentioned elsewhere (Maeland et al. 1964), the gold atom has a 
cubic closed-packed fcc crystal structure.  A detailed study has been 
performed (Liu et al. 2007) for the calculation of the molar concentration of 
spherical nanoparticles with different caps and for the determination of 
their extinction coefficients using a UV-Vis spectrophotometer. The authors 
proposed two equations for calculating the molar concentration of the 
AuNPs, and then used the calculated concentration in the Beer-Lambert law 
to determine the extinction coefficient. They obtained a linear relationship 
between the extinction coefficient and the AuNPs diameter independent of 
the solvent used in the preparation or even the capping of the molecules. 
Also, their results are compatible with the theoretical calculations of the 
AuNPs, and with another study that determined particle concentration and 
size using UV-Vis spectra (Haiss et al. 2007). Calculations were performed by 
first calculating the average number of gold atoms in the prepared spherical 
nanoparticles, from the density of the fcc gold and the atomic weight of gold 
(Cui et al. 2002, Zhang et al. 2004), using this equation: 
𝑁 =  
𝜋
6
𝜌𝐷3
𝑀
= 30.89602 𝐷3 
Where: N is the average number of gold atoms, ρ is the density for fcc gold 
(19.3 g/cm3), M is the atomic weight of gold (197 g/mole), and D is the 
diameter calculated from TEM or SEM. 
Then, the molar concentration is calculated according to this 
equation: 
𝐶 =  
𝑁𝑇𝑜𝑡𝑎𝑙
𝑁𝑉𝑁𝐴
In which: the Ntotal is equivalent to the initial amount of gold salt used in the 
preparation reaction, N is the average number of gold atoms calculated from 
the previous equation, while V is the volume of the reaction solution in liters, 
and NA is Avogadro's number. 
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The concentration is then used in the Beer-Lambert law equation to 
determine the nanoparticles’ extinction coefficient as shown in the following 
equation (Liu et al. 2007). 
𝐴 = 𝜀cl 
In which, A: is the actual absorbance of the sample, ε: is the molar 
extinction coefficient, C: is the concentration of the sample in Molarity, and 
l: is the path length, which is 1 cm3. 
Gold nanoparticles can be modified with different functional groups 
that allow the particles to be functionalized with different ligands, such as 
DNA, antigens, and antibodies. The sensitivity of the SPR of AuNPs to 
adsorption led to their use as labels in bioassays. We focus here on the 
different methods for using AuNPs to detect nucleic acids. 
Selected nucleic acids detection strategies using AuNPs 
Nucleic acid detection using AuNPs is based on two main 
mechanisms: (i) the unmodified AuNPs method, and (ii) the modified AuNPs 
method. The latter requires covalent modification of the AuNPs with an 
oligonucleotide specific to the target to be detected. AuNPs have been 
conjugated to oligonucleotides, and the attached DNA still has the ability to 
hybridize to its complementary sequence. The hybridization is selective, and 
the detection limit can reach 20 fmol/L (Jain 2007). The unique hybridization 
of the AuNPs probe with its complementary target sequence allows the 
assembly of the AuNPs, and a network of AuNPs is formed and detected by 
a color change (Storhoff et al. 1998) (e.g., a red to blue color change, with a 
red shift from 520 to 600 nm of the SPR).The advantage of using AuNPs as 
molecular recognition probes is the variety of the analytical techniques that 
can be used for their detection, including optical absorption, Raman 
scattering and electrical conductivity.  
1.1.3.1 Cross-linking method 
The modified AuNPs method involves the conjugation of a biological 
molecule to the nanoparticles surface for target detection. Detection of 
nucleic acids using AuNPs using cross-linking has been used (Elghanian et al. 
1997, Storhoff et al. 1998). The method is based on using two probes specific 
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to the target nucleic acid, one probe (oligonucleotide) being conjugated to a 
set of AuNPs via thiol oligonucleotides, while the other is conjugated to 
another set of AuNPs; both oligonucleotides  are complementary to the 
target DNA sequence at two different sites. Upon the addition of both 
modified AuNPs to the complementary DNA target, hybridization occurs 
between the target and the AuNPs modified with the specific target 
sequence, which leads to a decrease in the distance between the AuNPs. 
This results in the formation of a nanoparticles network, and thereby 
generates a red shift in the AuNPs SPR from 520 nm to ≥ 590 nm, which 
results in a change in the AuNPs color from red to purple, blue and then black 
according to the concentration of the target DNA (Figure 1.2). This method 
could be used in single-nucleotide polymorphisms (SNPs) detection by 
optimizing the annealing temperature at which the reaction occurs. Despite 
the high sensitivity and specificity of this method, which are obtained 
because the aggregation is based solely on the presence of the target, it 
suffers from many drawbacks, including AuNPs’ modification with 
oligonucleotides being a labor-intensive procedure, and the hybridization 
conditions of the target nucleic acid with the probe-modified AuNPs’ 
requiring optimization of the conditions regarding the kinetics and 
thermodynamics of nucleic acid binding, which on its turn requires tightly 
controlled conditions. Most importantly, this method cannot be used with 
long DNA and/or RNA sequences due to the steric hindrances associated 
with the probe-functionalized surface. To date, the cross-linking method has 
not been used for the detection of any nucleic acid from clinical samples, 
and more optimization is definitely needed for its application to the clinical 
diagnostics of nucleic acids from clinical specimens. 
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Figure 1.2: AuNPs cross-linking principle. The AuNPs are functionalized with DNA specific 
probes, then the target is added to the AuNPs solution and after denaturation and 
annealing, the nucleic acid target is hybridized with AuNPs modified probes leading to a 
formation of network of AuNPs/target shifting the color from red to blue indicating 
positive results. In absence of the target, the solution color remains red indicating 
negative results. 
1.1.3.2 Non- Cross-linking method 
As mentioned above, AuNPs have a high affinity for thiol groups. The 
non-cross-linking method is based on preparing AuNPs conjugated to a thiol-
modified probe in which the aggregation of probe-modified AuNPs is 
induced by the addition of high salt (more than 2 M NaCl). Upon addition of 
the complementary target nucleic acid, hybridization occurs. When the high 
salt-induced aggregation of AuNPs is prevented the solution remains red, 
indicating a positive result. In contrast, in the absence of a complementary 
sequence, the aggregation of AuNPs occurs after the addition of at least 2 M 
NaCl solution. In the absence of a complementary sequence to the AuNPs 
modified probe, the solution will turn blue upon the addition of a high salt 
concentration, while in the presence of a complementary target sequence, 
hybridization occurs, which prevents the high salt-induced aggregation and, 
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thus, the solution remains red. The non-cross-linking method is superior to 
the cross-linking method in that it is used mainly for the detection of longer 
nucleic acids more than 1500 bases. It has been used by many groups to 
detect different nucleic acids targets and SNPs (Baptista et al. 2006, Doria et 
al. 2007, Baptista et al. 2008, Liandris et al. 2009, Conde et al. 2010, Costa et 
al. 2010). The principle of the non-cross-linking method is shown in Figure 
1.3. 
 
Figure 1.3:  Principle of non-cross- linking assay for the detection of nucleic acids. The 
method depends on addition of high salt concentration to the AuNPs modified with target 
specific probe. In the presence of complementary target, hybridization occurs and no 
aggregation observed to the AuNPs and the solution remains red in color indicating 
positive sample. On the other hand, in the absence of complementary sequence, the 
AuNPs colloidal solution aggregates turning the color from red to blue indicating a 
negative sample. These color changes can be detected visually or spectrophotometrically. 
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1.1.3.3 Unmodified AuNPs method 
The addition of salt shields the surface charges of the AuNPs, which 
are typically negative due to the adsorption of negatively charged citrate 
ions to their surfaces, leads to aggregation of the AuNPs and a red-to-blue 
color shift (see above) (Li et al. 2004a). The unmodified AuNPs method is 
based on the principle that single-stranded DNA (ssDNA) adsorbs the 
negatively charged citrate-coated AuNPs, thereby preventing their salt-
induced aggregation and retention of their red color, even in the presence 
of sodium chloride. In contrast, double-stranded DNA (dsDNA) does not 
adsorb to AuNPs due to the repulsion between its negatively charged 
phosphate backbone and the negatively charged coating of citrate ions on 
the surfaces of the AuNPs. The idea behind this adsorption behavior of 
ssDNA on the negatively charged AuNPs is the fact that ssDNA can change 
its conformation by uncoiling, which results in the exposure of its 
nitrogenous bases to the surface of the AuNPs. Consequently, the attractive 
electrostatic forces between the DNA’s nitrogenous bases and the AuNPs 
allow the adsorption of the ssDNA, which prevents the salt-induced 
aggregation of the AuNPs. Double stranded DNA does not adsorb to AuNPs 
due to the repulsion between its negatively charged phosphate backbone 
and the negatively charged surface of the AuNPs. Therefore, when AuNPs 
are added to a saline solution containing the target DNA and its 
complementary unlabeled primer, the AuNPs aggregate (because the 
primers are not free to stabilize the AuNPs) and the solution color changes 
from red to blue to black according to the concentration of the target added. 
However, in the absence of the target nucleic acid or in the presence of a 
non-complementary sequence, the primers are free to stabilize the AuNPs, 
thus preventing their aggregation and the solution color remains red (Figure 
1.4). This method and concept were first introduced by Li et al., who 
developed colorimetric assay using unmodified AuNPs to detect different 
nucleic acid targets (Li et al. 2004a, Li et al. 2004b, Li et al. 2005). They used 
this method to detect amplified DNA and SNPs in (PCR-amplified) genomic 
DNA of fatal cardiac arrhythmia known as long QT syndrome extracted from 
clinical serum samples. They also applied this method to detect synthetic 
DNA sequences reaching a detection limit of 100 fmol. Furthermore, our 
group has used this method to detect hepatitis C virus (HCV) RNA amplified 
by (RT-PCR) for producing 250 bp amplicons in the 5-untranslated region of 
HCV genome in 10 HCV-positive serum samples. In our experiment, we 
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diluted the amplicons 30 times and attempted to detect the diluted samples 
using agarose gel electrophoresis stained with ethidium bromide, but no 
bands appeared. In contrast, these diluted samples were all detected using 
the unmodified AuNPs assay with a detection limit of 3 fmol (S. M. Shawky 
et al. 2009). The unmodified AuNPs-based nucleic acids detection method is 
superior to the modified methods because there is no need to functionalize 
the AuNPs with specific probes or oligonucleotides, which is labor-intensive 
and requires alkanethiol oligonucleotides that are expensive. In addition to 
the time needed for optimizing and functionalizing the AuNPs, which takes 
at least two days, the unmodified method allows the use of any primer 
without modification. Also, hybridization of the oligonucleotide and the 
target in the unmodified method is an independent step of the assay that 
eliminates the hassle of hybridization steps in the modified AuNPs assay. 
Finally, the unmodified method is simple, takes little time (less than 10 
minutes), and is sensitive, specific and cost-effective.  
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Figure 1.4: The principle of the unmodified AuNPs nucleic acids detection method. The 
target specific probes stabilize the AuNPs and prevent salt induced aggregation. Upon 
addition the complementary nucleic acid target, the probe hybridizes with its target, and 
the AuNPs aggregates by the action of the salt and color change occurs from red to blue. 
In absence of the target, the color solution remains red. 
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1.1.3.4 Fluorescence energy transfer and Quenching  
Light is a form of electromagnetic energy that has a dual 
wave/particle nature, and is emitted in discrete quantities called photons 
(Schulman. 1985). Molecules that are able to absorb light are known as 
chromophores. A process known as luminescence, which is the collective 
name for processes in which light is emitted from an electronically excited 
state. Luminescence is divided into two categories: fluorescence and 
phosphorescence. The difference between them is that fluorescence 
(fluorophores), their release of energy is immediate typically in order of 1- 
10 nano-seconds. On the other hand, phosphorescence release of energy 
occurs with a much lower rate in the order of milliseconds to second (Figure 
1.5).  Absorption of light photons (energy) by a molecule occurs in about 10-
15 seconds, which causes changes in the electron states of the molecule, 
thereby exciting the molecules' ground state electrons to a higher electron 
state above their thermal equilibrium. This excess energy will be lost via 1) 
chemical processes such as dissociation and photo-induced reaction and 2) 
physical processes. These physical processes fall within three categories: (i) 
excess energy emitted spontaneously (fluorescence and phosphorescence), 
(ii) excess energy that is thermalized by vibrational and rotational energy 
transfer (intersystem crossing (ISC), internal conversion (IC), and vibrational 
relaxation), and (iii) collisional quenching (static and dynamic quenching). 
Fluorescence and phosphorescence are the spontaneous emissions of this 
excess energy after 10-9 and (10-3-1) second, respectively. At longer 
wavelengths, the molecule stays in the excited state for about 1-10 
nanoseconds. This loss of excess energy is illustrated in Figure 1.5. 
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Figure 1.5: A modified Jablonski diagram showing the transitions between the excited and 
the ground state of the radiative energy loss (Fluorescence and phosphorescence) and the 
energy loss after excitation by light. S0: ground state, S1 & S2: excited states, T1: Triplet 
state, ISC: Intersystem crossing, IC: Internal conversion. 
There is a well-known phenomenon in fluorescence-based assays for nucleic 
acid detection, which is called FRET (Fluorescence or Förster Resonance 
Energy Transfer). The basic mechanism of FRET is that there are two 
molecules (one donor and one acceptor). When the donor is excited by light, 
instead of emitting this energy, the energy is transferred to the other 
molecule (acceptor), whose maximum absorption wavelength is within the 
range of the donor emission wavelength. This leads to the excitation of the 
acceptor molecule and, consequently, the energy is emitted at a longer 
wavelength. Simply, the FRET phenomenon occurs by exciting a donor 
molecule whose emission wavelength overlaps the excitation wavelength of 
the acceptor molecule and, thus, the emission of the acceptor is detected 
instead of the emission of the donor. The excitation energy of the donor is 
transferred to the acceptor via an induced dipole-dipole interaction. The 
efficiency of this energy transfer is dependent mainly on the distance 
between the two molecules used, which should not be more than 10 nm, 
and is governed by the equation: 𝐸 =
𝐑𝟎6
𝐑𝟎+𝐫𝟔
    (Yeh et al. 2005), Where R0 is the 
Förster transfer distance at which 50% of the energy transfer occurs, r is the donor-
acceptor distance, and E is the energy transfer efficiency.  
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Quenching, on the other hand, refers to a process that leads to a 
reduction of the fluorescence intensity of the fluorophore. This is due to a 
variety of molecular interactions, such as interactions of a quencher with a 
fluorophore in its excited state, which prevents the fluorophore energy 
transitioning to the ground state, and, therefore, deactivation occurs 
through collision between the fluorophore and the quencher. This is called 
collisional quenching. On the other hand, there is another type of quenching 
in which the fluorophore forms a stable complex with the quencher. In this 
case, the free fluorophore molecules number is reduced and no emission is 
observed (Eftink et al. 1981, Lakowicz 1999, Lakowicz 2006). The FRET and 
quenching phenomena are very convenient to use in several applications as, 
cell imaging and, single cell detection, and nucleic acid detection as Real-
Time PCR (Somogyi et al. 1985, Schroter et al. 2001, Shen et al. 2005, Rupcich 
et al. 2006, Bartolome et al. 2007, Slavoff et al. 2011). Despite the use of 
FRET and quenching in various biological techniques, including nucleic acids 
detection, there are two huge limitations that restrain their use in a wide 
range of molecular diagnostics. The first is that the Förster distance between 
the donor and the acceptor molecules should not exceed 10 nm. Secondly 
the emission maximum spectra of the donor should overlap with the 
maximum excitation spectra of the acceptor, which requires the precise 
selection of the donor and acceptor molecules in the FRET reactions. 
The energy transfer of a fluorescent dye to nanoparticles, including 
AuNPs, is termed Nanoparticle Surface Energy Transfer (NSET). AuNPs have 
the property of quenching the fluorescent dyes. The use of AuNPs as a 
quencher or acceptor of the energy transfer from a fluorophore is superior 
to that of conventional quenchers used in FRET because the distance needed 
for this transfer can reach approximately 100 nm, which is 10 times greater 
than that of the conventional FRET phenomenon. Additionally, it is able to 
quench several dyes with different emission spectra at the same time, which 
enables the development of multiplexing detection tools (Ray et al. 2006, 
Paresh Chandra Ray et al. 2007). The NSET interaction resembles FRET in that 
its energy transfer interaction is dipole-dipole in nature, although it is more 
efficient due to the free oscillating electrons on the surfaces of the AuNPs 
that leads to an increase in the probability of donor energy transfer. Thus, 
NSET is an improvement over FRET (Jares-Erijman et al. 2003, Zheng et al. 
2004, Jennings et al. 2006, Ray et al. 2006).  
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Because of the aforementioned properties of NSET, AuNPs have 
been used in many studies for the detection of many targets, including 
nucleic acids (Li et al. 2007).It has been employed to detect synthetic HCV 
RNA sequences using both non-cross-linking and/or unmodified AuNPs 
techniques with a detection limit of about 300 fM, by using a probe tagged 
with a fluorescent tag (Griffin et al. 2009a). It has also been used to detect 
the cleavage of dsDNA by nucleases (Ray et al. 2006). Moreover, AuNPs have 
been used as quenchers in a molecular beacon design (Dubertret et al. 
2001), which is a common chemistry used in real-time PCR. The design is 
based on ssDNA having a hairpin structure, with one end attached to a 
fluorophore and the other end to AuNPs. The close proximity between the 
fluorophores and the nanoparticles leads to NSET, and the fluorophores are 
quenched by the action of the AuNPs. In the presence of the target DNA, the 
beacon structure opens for hybridization with its target, and the distance 
between the AuNPs and the fluorophores increases, leading the latter to 
restore its fluorescence. The most interesting aspect of these experiments is 
that the use of AuNPs has increased the sensitivity of molecular beacons by 
about 100 fold. Also, our group has used the NSET phenomenon to detect 
HCV RNA in serum samples using fluorescein as a fluorescent dye and AuNPs 
of different sizes as quenchers (Shawky et al. 2011). The principle used in the 
assay was the same as for the unmodified AuNPs detection described 
previously; however, the probe used in the hybridization is tagged with 
fluorescein. In the absence of the target HCV RNA, fluorescein was quenched 
by the attachment of the probe to the surfaces of the AuNPs. Once 
hybridization occurs upon addition of the target, the tagged probe will 
hybridize with the target (HCV RNA), leaving the AuNPs’ surface and its 
emission is measured (Figure 1.6). This preliminary study was done on 12 
HCV-positive samples and 12 normal individuals, yielding a sensitivity and 
specificity of 92%, with a detection limit of 10 fM. Moreover, we have 
measured the quenching effect of AuNPs of different sizes (15, 40 and 70 
nm) on fluorescein labeled probes, and found that as the size of the AuNPs 
increases, the quenching efficiency increases. This study is still in progress 
and more experiments are needed to identify the optimum conditions for 
the detection. 
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Figure 1.6 Schematic diagram of the NSET based detection. The fluorophore conjugated 
probes adsorbed on AuNPs leading to quenching the fluorescence signal of fluorophore 
due to the vicinity of the fluorophore and AuNPs. The target RNA binds to the probe and 
forms a double stranded RNA, thus increasing the fluorophore/AuNPs distance after 
hybridization, and decreasing NSET efficiency, leading to an enhanced fluorescence signal 
as the output signal.  Moreover, the AuNPs aggregated by the action of the salt leading to 
a color change from red to blue. 
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1.1.3.5 Selected Immuno-assays by gold nanoparticles 
Gold nanoparticles can be conjugated to antibodies or antigens for 
use in immuno-assays, and protein chips can also be developed. For 
example, several antibodies against HCV and HBV have been detected using 
gold nanoparticles, and silver enhancement staining was used for the 
amplification of the detection signal. This method has high sensitivity and 
specificity with a detection limit of 3 ng of antibody/ml, it is time saving as 
the results are available in less than 40 min.; it is also less costly than 
currently used methods (Duan et al. 2005). This method has been applied to 
detect antibodies against cytomegalovirus (CMV), Toxoplasma  gondii (Tox), 
rubella virus (RBV), herpes simplex virus (HSV), and coxsackie virus B6 (CVB6) 
(Liang et al. 2004). The results showed that this method is sensitive (with 
detection limit of 1 pg of IgG immobilized on slides or 2.75 ng/ml IgG in 
solution), specific, with multiplexing capabilities, and saves time and money, 
hence it is attractive for clinical applications. The sensitivity of the AuNPs’ 
based assays is due to the aforementioned properties of the gold 
nanoparticles such as their Surface Plasmon Resonance (SPR) that lies within 
the visible frequencies and the main reason in AuNPs’ strong optical 
absorption and scattering properties. This in turn, have been used in 
colorimetric detection of different analytes by measuring changes in the 
refractive index of AuNPs’ caused by the absorption of the target. Moreover, 
the high surface to volume ratio of the AuNPs’ allows signal detection 
enhancement and high sensitivity of the assay (Baptista et al. 2008, Ambrosi 
et al. 2010, Sau et al. 2010). 
Recently, gold nanoparticles with a different surface modification 
and shape were compared for evaluating the most sensitive method for 
immuno-assays (Radha Narayanan 2008). When used as extrinsic Raman 
labels (ERLs) in immuno-assays based on surface enhanced Raman 
Scattering, it was found that the limit of detection of cetyl-tri-methyl-
ammonium bromide (CTAB) cubic gold nanoparticles is about 340 times 
below that for the spherical citrate gold nanoparticles, and 200 fold more 
sensitive. These results show that new immuno-assays could be developed 
using cubic gold nanoparticles that are capped with CTAB to set up more 
sensitive and yield lower detection limit assays.  
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Iron oxide nanoparticles 
Iron oxides exists in a variety of chemical compositions, such as 
goethite, akaganéite, lepidocrocite, feroxyhyte, magnetite and maghemite 
(Rochelle M. Cornell et al. 2003). The most important iron oxides used in 
biomedical applications are the magnetite (Fe3O4) and its oxidized form 
maghemite (γ-Fe2O3) (Cao et al. 2005). Magnetic nanoparticles have unique 
physical, chemical, and mechanical properties at nano-scale, although the 
most important advantage of magnetic nanoparticles is their magnetism. 
Magnetic properties (coercivity, susceptibility, crystallographic structure, 
magnetic anisotropic energy, and vacancies) have been enhanced at the 
nano-scale level, which led to an emergence of magnetic nanoparticles with 
precisely tuned sizes and shapes. The two latter properties are parameters 
that greatly affect magnetism (Jun et al. 2008). The decrease in the size of 
magnetic particles to the nano-scale level has led to what is called 
superparamagnetism as a result of changing the magnetic spin direction, 
which leads to a net magnetization of zero. Moreover, nano-scale size affects 
the magnetic coercivity, which is the measure of the ability of the 
ferromagnetic material to withstand an external magnetic field. Magnetic 
nanoparticles have a high coercivity and low Curie temperature. Both 
magnetite and maghemite have supermagnetism properties at room 
temperature (Amyn S. Teja et al. 2009). Furthermore, the saturation of the 
magnetization of nanoparticles is dependent on their size, which in turn 
affects their magnetic resonance signal enhancement capabilities (Lee et al. 
2007). Also, as magnetic nanoparticles, they possess large magnetic 
moments when a magnetic field is applied, and they are attracted to a high 
magnetic flux density. This can be useful for applications in drug targeting, 
bio-separations, and hyperthermia treatments.  
Synthesis of iron oxide nanoparticles 
Different strategies are followed for the synthesis and preparation 
of magnetic nanoparticles. The most important is the Co-Precipitation 
method, which is based on the mixing of ferric and ferrous ions in a basic 
medium at room or elevated temperature. The salt type, ratio of ferric and 
ferrous ions, pH, stirring rate, and reaction temperature affect the 
morphology, structure, size, and the magnetic properties of the produced 
nanoparticles (Vu Thien Binh et al. 1998, Wu et al. 2008). The thermal 
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decomposition method has the main advantage of producing highly mono-
dispersed particles with a narrow size distribution. The method is based on 
the decomposition and oxidation of iron salts, such as cobalt, N-nitroso-
phenyl-hydroxylamine, acetyl-acetonate and nitrate salts, in an organic 
phase solution under high temperature (Rockenberger et al. 1999, Hyeon et 
al. 2001, Sun et al. 2002, Woo et al. 2004). However, the particles produced 
by this method are dissolved only in organic solvents, which is the main 
disadvantage of the thermal decomposition method. The micro-emulsion 
method is one of the methods used in the synthesis of magnetic 
nanoparticles. According to the IUPAC definition, a micro-emulsion is a liquid 
mixture in which water, oil and a surfactant are dispersed. The system is 
isotropic and thermodynamically stable, and the dispersed domain size is 
between 1 and 100 nm (Stanislaw Slomkowski et al. 2011). A variety of self-
assembled structures (spherical, cylindrical and lamellar) can be produced 
based on the phase transition that occurs during the emulsification process 
(Solans et al. 2005).  This concept has been utilized for the production of 
magnetic nanoparticles having high saturation magnetization values, 
controlled size, and a highly dispersed size range with very narrow size 
distribution (Tourinho et al. 1990, Vidal-Vidal et al. 2006, Chin et al. 2007). 
However, the process needs several washing steps and further particle 
stabilization is required in addition to the high temperature needed during 
the synthesis process. The hydrothermal method is a synthesis technique 
for producing single crystals from substances in a high temperature aqueous 
solution at high vapor pressure. The advantage of this method is the ability 
to achieve remarkable structures, such as nano-cubes and hollow sphere 
iron oxides (Titirici et al. 2006, Wang et al. 2007). However, a drawback of 
this method is the need for an expensive autoclave (K. Byrappa et al. 2001). 
Hydrothermal synthesis has been reported by several groups for the 
production of magnetic nanoparticles with good magnetization value, 
mono-dispersity and controlled size and morphology (Wang et al. 2003, Jing 
et al. 2004, Giri et al. 2005, Daou et al. 2006, Zheng et al. 2006, Hu et al. 
2007). A number of strategies have been developed for the surface 
modification of iron oxide nanoparticles with oligonucleotides, antibodies, 
peptides, small molecules and carbohydrates.  
Due to the aforementioned properties, magnetic nanoparticles have 
numerous medical applications, including in vitro diagnostics and molecular 
recognition in immuno-assays, bio-separation, and cell sorting, and in vivo 
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imaging as a result of their potential usefulness as contrast agents for 
magnetic resonance imaging. Finally, they can serve as drug/gene delivery 
systems (Zhao M. et al. 2002, Catherine C Berry et al. 2003, Shinkai et al. 
2004, Ito et al. 2005, Laconte et al. 2005, Weissleder et al. 2005, S. c. Wuang 
et al. 2006). 
Magnetic nanoparticles applications 
1.2.2.1 In-Vitro Diagnostics 
Superparamagnetic nanoparticles have positive properties due to 
their small size, high surface area, stability, and ease of surface 
functionalization. When bound to an antibody, antigen or oligonucleotide, 
they can easily detect specific (bio) molecules, structures, or microorganism. 
Additionally, their magnetic property has the advantage of eliminating or 
reducing the time needed for adsorption and separation steps, thus 
decreasing the overall time needed for the assay. Upon exposure to an 
external magnetic field, the magnetic signal is detected with a sensitive 
magnetometer and the target bound to the magnetic nanoparticles can be 
identified because the unbound molecules will disperse in all directions and 
no net magnetic signal is produced (Jain 2005). In an immuno-assay for 
allergen-specific immunoglobulin E detection, a novel magnetophoretic 
immuno-assay was developed based on the magnetophoretic deflection 
velocity of a micro-bead, which is proportional to the associated magnetic 
nanoparticles under an enhanced magnetic field gradient in a micro-channel 
(Hahn et al. 2007).The test was performed by conjugating polystyrene micro-
beads to Dermatophagoides farinae (D. farinae) and D. pteronyssinus, and 
incubation with serum samples. The mixture was then reacted with 
magnetic nanoparticles conjugated with anti-human IgE using a sandwich 
immune reaction. When an external magnetic field is applied 
perpendicularly to the flow direction of a micro-fluidic channel, the magnetic 
particles exert a magnetic force, which drives their magnetophoretic lateral 
movement. This velocity correlated well with the concentration of allergen-
specific IgE in serum (Figure 1.7). The detection limits of the allergen-specific 
human IgEs for D. farinae and D. pteronyssinuswere were 565fM (0.045 
IU/mL) and 268 fM (0.021 IU/mL), respectively. This method is fast, sensitive, 
and only tiny amounts (~10 µl) of serum are needed. Also, magnetic 
nanoparticles have been used to screen telomerase activity in biological 
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samples in which, upon annealing of the nanoparticles with telomerase-
associated TTAGGG repeats, the magnetic state of the nanoparticles was 
switched and detected by a magnetic reader (Grimm J 2004). Moreover, 
magnetic nanoparticles have been used for cell tracking and for calcium 
sensing (Jain 2007). Also, dextran-coated iron oxide nanoparticles (70 nm) 
have been used for the development of an immuno-assay for the detection 
of whole blood C-reactive protein (CRP). The output signal of the detector 
was proportional to the CRP concentration in the whole blood sample (4 µl), 
with a detection limit of 3 mg/L (Ibraimi et al. 2006).  
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Figure 1.7 Schematic diagram showing the detection of Dermatophagoides Farinae 
antigens in serum samples using magnetic nanoparticles. The steps of the assay is 
described in the diagram. 
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1.2.2.2 Biomolecules Separation 
Magnetic nanoparticles are currently used commercially for the 
separation of various biomolecules from clinical specimens. They are used in 
the separation of DNA, RNA, proteins, antigens, antibodies and viruses. The 
introduction of magnetic separation of biomolecules from a mixture was a 
breakthrough by increasing sample purity, selectivity and purity of the target 
needed to be analyzed, and, at the same time, decreasing the overall time 
taken for the completion of the assay. Magnetic separation can be used as a 
separate step for target capturing and purification from a sample, and it 
could also be used as a diagnostic tool. 
Table 1.1       Examples of some commercially available magnetic particles, their uses and 
suppliers 
Vendor Products Examples Clinical use Website 
Solulink 
 
Magnetic beads range in size from 0.8 to 
2.8 um in diameter, functionalized with 
amino, Streptavidin, and hydrophilic 
polymers 
Purification of different 
biomolecules such as nucleic acids 
and  antibodies 
http://store.sol
ulink.com 
 
Thermo Scientific 
Pierce 
 
Magna beads ranging in diameter from 1 
to 4 um. Available with various coating 
as: protein A, Protein G, Streptavidin, 
anti-mouse & anti-rabbit Ab. Also, 
functionalized with amino or carboxyl 
groups. 
Cell sorting, immuno-assays, 
proteins purification, and nucleic 
acid purification 
http://www.pie
rcenet.com/cat/
pierce-
magnetic-beads 
Invitrogen 
Dynabeads ranging in size from 1to 2.8 
um in diameter. Available with different 
coatings as: Streptavidin, Protein A or G, 
secondary antibodies, and amino groups. 
Cell separation & sorting, immuno-
precipitation assays, nucleic acid 
capturing & purification. 
http://www.life
technologies.co
m/dynabeads 
Nanocs 
 
Magnetic nanoparticles from 10 nm to 1 
um. Available functionalized with 
hydroxyl, amine and carboxyl groups. In 
addition with folic acid, Streptavidin, 
protein A & protein G and fluorescent 
tags nanoparticles such as fluorescein , 
cy3, cy5 and Rhodamine B. 
Used in different biomolecules 
separations, diagnostics, cell 
imaging and cells separation. 
http://www.na
nocs.net/nanop
article/magneti
c_nanoparticles.
html 
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Hepatitis C virus (HCV) 
Hepatitis C is a blood-borne liver disease caused by the hepatitis C 
virus (HCV), which was identified in 1989 and prior to that was described as 
non-A-non B hepatitis (Choo et al. 1989). It is a major public health problem. 
According to the World Health Organization, about 200 million people, or 
3% of the world population, are currently infected with HCV as the result of 
blood transfusions in times where the virus was not identified yet, but 3-4 
million persons are still newly infected each year. Additionally, there are 170 
million chronic carriers at risk of developing liver cirrhosis and/or liver cancer 
due to HCV infection only (Who). Moreover, a recent study found that Egypt 
has the highest prevalence of HCV in the world. About 14.7% of the Egyptian 
population is chronically infected with HCV, and it is estimated that more 
than 500,000 new HCV infections occur per year in Egypt (Miller et al. 2010), 
i.e. between one sixth and one eight of the estimated new cases in the world, 
and which translates to a rate of ~6.9/1,000 persons per year in Egypt being 
newly infected with the virus.  
HCV is a small, enveloped RNA virus belonging to the Flaviviridae 
family, genus Hepacivirus, which comprises a group of highly variable strains 
or isolates. They are classified into six groups or clades based on a 
phylogenetic analysis of full-length or partial sequences of different HCV 
strains. The clades differ by 31 to 34% in their nucleotide sequence and 
about 30% of their amino acids sequence (Simmonds et al. 1993, Higuchi et 
al. 2002). Each clade contains one or more genotypes. Until now, 11 
genotypes and more than 70 subtypes have been described. Different 
genotypes differ by more than 30% of their nucleotide sequence, while 
subtypes have a nucleotide difference of 20-25% (Simmonds 2004). HCV 
genotypes are distributed worldwide, with different genotypes being more 
common or predominant in different areas. HCV undergoes constant 
mutation in newly replicating viruses within chronically infected patients. 
This results in high numbers of HCV populations with diverse nucleotide 
sequences (Simmonds 2004). These newly formed viruses are termed HCV 
quasi-species. It is believed that certain quasi-species are responsible for the 
development of chronic hepatitis, vaccine failure and the rapid development 
of drug resistance (Boyer et al. 2000). 
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HCV life cycle 
The HCV genome is a 9.5 Kb-long, single-stranded RNA molecule of 
positive polarity, which means that the HCV RNA similar to the mRNA in that 
it can be immediately translated by the host cell and viral proteins. It 
contains a single open reading frame (ORF) flanked by 5´ and 3´ un-
translated regions (UTR) of 341 and about 230 nucleotides, respectively. The 
ORF encodes a polyprotein of about 3000 amino acids. Both the 5´ and 3´ 
UTRs bear highly conserved RNA structures essential for poly-protein 
translation and genome replication (Penin et al. 2004). The 5' UTR is 
uncapped and contains an Internal Ribosomal Entry Site (IRES). The IRES is 
essential for the attachment of the HCV genome to host ribosomes 
(Bartenschlager R 2004) and for the recruitment of host proteins that initiate 
viral poly-protein translation. This function is highly dependent on the 
conservation of the IRES secondary structure (Odreman-Macchioli et al. 
2000, El Awady et al. 2009). The poly-protein undergoes a complex series of 
co- and post-transcriptional cleavages in the endoplasmic reticulum, which 
is catalyzed by both host and viral proteases to yield 10 mature HCV proteins 
in infected cells (Penin et al. 2004). These proteins are divided into structural 
proteins, the core, envelope1 (E1), and envelope2 (E2), and non-structural 
proteins, including P7, NS2, NS3, NS4A, NS4B, NS5A, and NS5B. The primary 
host cells for HCV are hepatocytes (Moriishi K 2003), and the progeny virions 
leave the host cell by the constitutive secretory pathway (Lindenbach et al. 
2005). Replication has also been described for peripheral blood 
mononuclear cells (PBMCs), as well as several T and B cell culture lines 
(Maggi et al. 1999).  
Current therapeutic options 
There is currently no approved vaccine available for HCV due to HCV 
heterogeneity and its ability to constantly mutate during infections (Prince 
et al. 2001, Simmonds 2004, Previsani Nicoletta et al. 2013, Who 2011). All 
the developed vaccines are still under trials, and most of them are thus far 
targeting only genotype 1, subtypes a & b.  
Standard alfa-interferon (IFN), PEGylated IFN, and the antiviral drug 
ribavirin were the only United States Food and Drug Administration (FDA)-
approved medications for the treatment of hepatitis C (Manns Mp 2001). 
Recently, four novel anti-HCV drugs with high efficacy were approved by the 
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FDA. Treatment is accomplished when patients achieve a sustained 
virological response (SVR) 24 weeks after treatment termination, as 
evidenced by negative RT-PCR of the patient’s blood sample. Because HCV 
infections have the aforementioned serious outcomes in addition to their 
genome heterogeneity, it is important to monitor responses to treatment. 
Diagnostic tests play a crucial role in addressing this aggressive viral disease. 
Moreover, the FDA recommended all baby boomers to get tested for HCV 
[i.e., 80 million people to be tested] (Smith et al. 2012, Nave 2013, Zagaria 
2014). This will encourage more people to get tested. 
Current diagnostic methods 
Laboratory test play a crucial role in management of HCV infection, 
and the heterogeneous nature of the infection augments the importance of 
HCV tests. Currently, several tests are used in the diagnosis and monitoring 
of HCV-infected patients. The tests fall into two main categories. Firstly, 
serological tests such as enzyme-linked immuno-assays (EIAs), which are 
used for screening, blood donations and diagnosis of symptomatic patients. 
Secondly, recombinant Immune Blot assays (RIBA), which are used primarily 
for confirmation of HCV infection (Atrah et al. 1996, Sarrazin 2004, Chevaliez 
et al. 2007). The second category comprises tests used for detection of HCV 
RNA (HCV viremia); including PCR- based assays (qualitative and quantitative 
including real-time PCR) and branched-DNA (b-DNA) assay. These tests are 
used mainly for therapeutic monitoring, prognostics, genotyping and 
mutational analysis for determination of adequate treatment regime, to 
reduce the treatment window period (Damen et al. 1995, Chevaliez et al. 
2006, Scott et al. 2007).  
1.3.3.1 Biochemical markers and serological tests  
Elevation in serum liver trans-aminases, alanine amino-transferase 
(ALT) and aspartate amino-transferase (AST) usually accompany hepatic 
dysfunction and/or infection, including HCV infections. However, the serum 
ALT does not accurately predict the presence of HCV infection. Thus, extra 
serological tests should be done to detect anti-HCV antibodies within 
suspected individuals. Anti-HCV antibodies detection, which is accomplished 
using EIA, is the first line in HCV diagnosis. Three different generations of EIA 
have been developed, with improvement in the sensitivity of the assay in 
each generation. EIAs have an estimated specificity range of 98.8% to 100% 
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in immune-competent patients, while in immune-suppressed patients, the 
sensitivity of EIAs decreased in range from50% to 95% according to the level 
of immune-suppression (Atrah et al. 1996). 
RIBA is the second line in detecting anti-HCV antibodies, and it is 
usually used as a confirmatory test to avoid the false positives done of the 
EIA tests. It has also been developed in several waves, roughly leading to 
three generations of tests. Detection of mounted immune-reactivity against 
two or more HCV antigens is considered a positive test result. Immune-
reactivity against only one HCV antigen (core, NS3 and/or NS4) is classified 
as an intermediate result and needs additional confirmatory tests. If no 
immune-reactivity is detected, the test is considered negative (Sarrazin 
2004). 
A clear drawback of the serological tests is that they are not suitable 
for detecting acute infections because antibodies can only be detected after 
at least three weeks of the onset of the infection. In addition, and as 
indicated above, they will not be suitable for the immune-suppressed 
patients. 
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1.3.3.2 Nucleic acid testing (NAT) 
NAT provides a direct measure of the HCV RNA and, thus, an 
estimation of the viral load, disease progression, and the response to 
therapy. However, NAT has limitations, such as high cost and unreliability in 
point-of-care testing. Two main strategies are currently used for detecting 
HCV RNA in clinical specimens. The first is based on target amplification, such 
as PCR-based techniques and transcription-mediated amplification (TMA), 
while the second is based on signal amplification, including branched DNA 
technology (b-DNA). 
TMA is based on the multiplication of viral RNA in vitro, and 100 to 
1000 RNA copies are synthesized in one cycle. These amplicons re-enter the 
TMA cycle and become templates for the next replication cycle. Single- 
stranded fluorescently labeled probes are then hybridized to the RNA 
amplicons and the chemiluminescent signal of the target sequence is 
detected (Scott et al. 2007) 
PCR -based techniques are classified into conventional PCR and real-
time PCR. Both of them are dependent on the amplification of the most 
conserved region in the HCV genome, which is the 5' UTR, and the detection 
of the amplicons’ fluorescence. Many commercial assays based on PCR 
techniques with different sensitivities and specificities are available (Germer 
et al. 2002).  
Real-time PCR is more promising than the conventional method, as 
it is more sensitive, it is fully automated and it is based on the use of 
fluorescent probes that allows the monitoring of the amplified product on 
real time basis, without the need for post- amplification detection as e.g. 
ethidium bromide stained gel electrophoresis. The detection limit can reach 
15 IU/ml (Halfon et al. 2006). Moreover, multiplexing is achievable using 
real-time PCR, and a number of assays have been applied for the 
simultaneous detection of several viral genomes (Read Sj 2001). 
Finally, the b-DNA measures nucleic acid molecules through linear 
signal amplification. It is a sandwich HCV RNA hybridization in which the viral 
RNA is captured in a micro-well by a set of specific synthetic oligonucleotides 
(called capture probes) that are specific to the highly conserved HCV RNA 
region of the 5'UTR. A set of target specific probes called (label extenders 
and capture extenders) then hybridizes to both the viral RNA and the pre-
Introduction 
Page 32 
amplifier probes. The capture extenders are designed to hybridize to both 
the target nucleic acid and capture probes that are attached to the micro-
well, while the label extenders are designed to hybridize to adjacent regions 
on the captured target and provide sequences for the preamplifier probes. 
The latter leads to the formation of a stable hybrid only if it hybridizes to 2 
adjacent label extenders; it also has other regions to hybridize to multiple b-
DNA amplifier molecules that create a branched structure. 
 Finally, multiple copies of alkaline phosphatase (AP)-labeled probes, which 
are complementary to b-DNA amplifier sequences, then hybridize to this 
immobilized complex. The AP bound complex is then incubated with a 
chemiluminescent substrate, and the signal is quantified by photon counting 
in a luminometer, which is directly related to the amount of HCV RNA 
present in each sample (Urdea et al. 1997, Scott et al. 2007). The b-DNA 
assay is highly specific and sensitive for HCV quantitation. Furthermore, as 
many as 18 b-DNA molecules are bound to each HCV RNA, and as many as 
810 separate AP molecules per HCV RNA can be hybridized. This provides a 
decisive enhancement of the signal, leading to increase in the sensitivity of 
the test, which can reach a lower detection limit of 615 IU/ml. A prime 
advantage of the b-DNA is that it is based on signal rather that target 
amplification, thus minimizing the chances of contamination. Examples of 
commercial available HCV molecular assays are summarized in Table 1.2. 
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Table 1.2:   Selected commercially available HCV RNA detection assays. 1 IU/ml equivalent 
to 2-5 copies/ml. RT-PCR: Reverse Transcriptase polymerase chain reaction, TMA: 
Transcription mediated amplification. b-DNA: branched-DNA 
Assay Method 
Lower limit of 
detection 
(IU/ml) 
Specificity References 
Amplicor HCV 
v2.0 
RT-PCR 
50 97.8%-100% 
(Podzorski 2002, Chevaliez et al. 
2006) 
Cobas 
Amplicor HCV 
v2.0 
50 
100% at 
detection 
cutoff (50 
IU/ml) 
(Germer et al. 2002) 
Amplicor HCV 
Monitor v2.0 
600 98% (Tsou et al. 2005) 
Cobas 
Amplicor HCV 
Monitor v2.0 
600 100% (Eissa et al. 2014b) 
Versant HCV 
RNA 
qualitative 
assay 
TMA 9.6 96%- 100% (Tarrytown 2002) 
Versant HCV 
RNA 3.0 Assay 
b-DNA 
615 
98.8% at 
detection 
cutoff ( 615 
IU/ml) 
(Germer et al. 2002) 
Quantiplex 
HCV RNA 2.0 
200,000 HCV 
equivalents/ml. 
97% 
(Germer et al. 2002, Trimoulet et 
al. 2002) 
Cobas 
TaqMan HCV 
test 
Real-time PCR 
15 95% 
(Chevaliez et al. 2006, Halfon et 
al. 2006) 
Abbott Real 
Time HCV 
assay 
30 or 12 based on 
use of 0.2 or 0.5 ml 
of plasma for 
analysis, 
respectively 
≥99.5% 
(Chevaliez et al. 2006, Halfon et 
al. 2006, Arnold et al. 2013) 
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Many aspects of HCV infection, such as diagnosis, monitoring, and 
treatment, have evolved rapidly in the last decade. However, the sustained 
response, and the factors involved in HCV persistence, as well as developing 
chronic disease are still under debate. Thus, much work is needed to assess 
many features, including the decision to initiate therapy, the early detection 
of HCV, and how chronic infections develop. Therefore, novel HCV RNA 
diagnostic techniques, which are simple, cheap, rapid, with acceptable 
sensitivity and specificity, are urgently needed. 
 This can open the door for introducing nanotechnology to HCV 
diagnosis and, thus, applying point-of-care testing in HCV diagnosis and 
therapeutic monitoring.   
Tumor Markers 
The development of non-invasive methods for the early and specific 
detection of different cancer types is urgently needed. The tumor markers 
field is highly dynamic, and reliable diagnostic and prognostic tumor markers 
are rapidly evolving as non-invasive methods for early cancer detection. The 
overall success is highly dependent on gathering information from various 
disciplines, such as genomics, proteomics, transcriptomics and epigenetics. 
There still is a major clinical need for a sensitive, specific, cheap, simple and 
non-invasive tumor biomarkers, and for techniques that could be used in the 
routine screening of individuals at high risk for cancer, as well as for the early 
diagnosis of low-grade tumors (Sanna Eissa et al. 2013). Nucleic acids (DNA, 
RNA and micro-RNA)-based assays of specific genes that are related to the 
cancer type could be a promising non-invasive method for the early 
detection of tumors, enabling the prediction of responses to treatment and 
the screening of high-risk individuals. In this work, we have selected two 
tumor markers for urinary bladder and breast cancer as examples of the 
development of novel nano-assays for their early detection. 
Urinary Bladder Cancer 
Bladder cancer is a significant public health problem worldwide, and 
is one of the five most common malignancies. It is the second most common 
tumor of the urogenital tract, and the second most common cause of death 
in patients with such malignancies (Eissa S. et al. 2014). The highest 
incidence rates are found in Europe, North America and Northern Africa 
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(Jemal et al. 2011). According to the annual report of the American Chemical 
Society (ASC) (Society 2014), in 2014, about 74,000 new cases are estimated 
to occur in the USA, with about 16,000 estimated deaths. In Egypt, urinary 
bladder cancer is the main cause of cancer in males and the second one in 
females (Salem et al. 2012).  
Although the main symptom of bladder cancer is painless 
hematuria, no other symptoms are found in the early stage of tumors 
(Kaufman et al. 2009). Moreover, these tumors have a 30% to 70% 
recurrence rate and a strong tendency to progress to invasive cancers in 10% 
to 30% of patients, with an increased risk of metastasis and subsequent 
mortality (Howlader N et al. 2011). Thus, early detection of bladder cancer 
is urgently needed to improve its prognosis and long-term survival. 
Cystoscopy is considered the gold standard for detection of bladder cancer 
(Smith et al. 2013). It enables the direct visualization of the urothelium and 
the subsequent characterization of the tumor. However, cystoscopy is rather 
invasive, expensive and labor intensive (Avritscher et al. 2006, Margel et al. 
2011). Finally, flexible cystoscopy has a definite false-negative rate, 
particularly for carcinomas in situ (Sapre et al. 2014). Urine cytology 
(microscopic examination of cells from urine specimens under light 
microscope to look for cancerous cells) is a non-invasive test widely utilized 
with cystoscopy for both screening and surveillance of tumor recurrence. It 
is generally acceptable for detecting high-grade bladder tumors. However, 
classical cytology has a low sensitivity and cannot be used to identify low-
grade cancer cells. In addition, the accuracy of the diagnosis in urine cytology 
is dependent on the level of expertise of the cytopathologist (Vrooman et al. 
2008). 
In addition to cystoscopy and cytology, numerous urine tests have 
been developed for the detection of bladder cancer, including bladder tumor 
antigen (BTA), fibrin degradation products, nuclear matrix protein 22, 
Immunocyt, fluorescence in situ hybridization and hyalouronic 
acid/hyalouronidase. Most of these markers have a higher sensitivity than 
urine cytology, although their specificity is generally lower, and urinary tract 
infection, benign prostatic hypertrophy, and renal calculi can reduce their 
accuracy (Van Rhijn et al. 2005, Vrooman et al. 2008, Sapre et al. 2014). 
Although several urinary biomarkers have been investigated and have 
received FDA approval for diagnosis, none of these has been implemented 
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in practice guidelines due to an insufficiency of clinical evidence (Kamat et 
al. 2013). At present, there is no consensus regarding their role in enhancing 
or replacing cystoscopy and/or cytology (Yossepowitch et al. 2007). 
Identifying novel biomarkers in urine has the great advantage in that 
urine specimens can be collected and obtained at high quantities. Moreover, 
investigation of RNA-based tumor markers (mRNA and/or micro RNA) in 
different samples is a rapidly evolving strategy not only in bladder cancer 
detection but also for the diagnosis of other tumors (Cortez et al. 2011). 
1.4.1.1 Hepatoma Up-Regulated Protein (HURP) 
Hepatoma up-regulated protein (HURP) is an important cell cycle 
regulator that plays a role in the carcinogenesis of different cancer types, 
including urinary bladder cancer cells (Chiu et al. 2002, Huang et al. 2003, 
Tsou et al. 2003, Tsou et al. 2005). Cells over-expressing HURP appear to 
have the characteristics of tumor cells, with a reduced dependence on 
extracellular growth factors and the potential to exhibit anchorage-
independent growth. In a very recent study (Eissa et al. 2014b), HURP RNA 
was measured  in the urine specimens of 211 patients with bladder cancer, 
71 benign bladder lesions and 62 normal controls using semi-quantitative 
RT-PCR. The assay exhibited 78.7% sensitivity and 94% specificity for bladder 
cancer detection. Thus, HURP RNA could be considered as a potential non-
invasive biomarker for urinary bladder cancer diagnosis. 
Breast Cancer 
Breast cancer still remains the most common cancer among women 
and the major cause of cancer mortality among women in both developed 
and developing countries (Zeeneldin et al. 2013). The ACS, in its 2014 annual 
report (Society 2014), estimated that about 232,670 (29% of cancer cases) 
new cases of breast cancer will occur in women, with about 40,000 (15%) 
estimated deaths in the USA in 2014. Worldwide, breast cancer is the leading 
cause of cancer deaths in females, accounting for about 14% of their cancer 
related mortality, and 23% of the total cancer diagnoses in females (Jemal 
et al. 2011, Ferlay et al. 2012). Also, it is considered one of the most four 
common cancers in Europe, and its incidence has increased in Western and 
Northern Europe in the last two decades (Arnold et al. 2013). In Egypt, it is 
the most common cancer in females, accounting for 37.7% of their total 
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cancer cases and 29% of their cancer-related deaths (Siegel et al. 2012). As 
for other cancer types, no signs or symptoms and/or pain are associated with 
breast tumors in their early stage, and even large tumors are painless, 
although they may appear as an internal swelling in the breast. The main 
problem in breast cancer is that even very small lesions or tumors could lead 
to metastasis (Misek et al. 2011).  
There are many risk factors related to breast cancers, such as 
obesity, heavy smoking, and alcohol consumption, the use of combined 
estrogen and progestin pills and, most importantly, women having a family 
history with breast and/or ovarian cancer. Until now, the most effective 
method for breast cancer diagnosis and/or screening is the standard 
mammography; it usually detects cancer at early stages. However, the 
mammography technique has low specificity and/or sensitivity, and lesions 
less than 0.5 cm in size cannot be detected by mammography. Additionally, 
its sensitivity is lower in young women and those with dense breasts. A 
combination of digital mammography and magnetic resonance imaging may 
increase the sensitivity and specificity. However, for most women, with 
abnormal mammograms, the tissue biopsies provide the final decision of the 
diagnosis (Misek et al. 2011, Society 2014). The shift toward an earlier 
diagnosis of breast cancer due to improved imaging methods and screening 
programs highlights the need for new factors and combinations of 
biomarkers to quantify the residual risk to patients, and to indicate the 
potential value of additional treatment strategies (Bartlett et al. 2010). A 
broad range of protein biomarkers has been investigated as potential and 
predictive factors for breast cancer detection, including such well-
established factors as Ki-67 and HER-2. Other investigational prognostic 
factors include mitosin, apoptosis-related proteins, cell cycle regulators, 
plasminogen activators and inhibitors, and angiogenesis-related proteins 
(Cecchini et al. 2012). On the other hand, genetic alterations, such as gene 
rearrangements and mutations, as well as their roles in regulating cancer cell 
growth and metastasis, are part of a highly evolving field of research for 
investigating novel genetic biomarkers, which are usually seem to be more 
reliable than most of the protein biomarkers (Bhatt et al. 2010). Therefore, 
nucleic acids (DNA, RNA and miR)-based assays of specific genes could be 
used as tools for breast cancer detection and/or screening, in addition to 
predicting responses to treatment. 
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1.4.2.1 Histidine-Rich Glycoprotein (HRG) 
Histidine-rich glycoprotein (HRG) is a 75 KDa α2-glycoprotein 
synthesized by the liver, and it is also found in plasma and platelets (Leung 
et al. 1983, Hulett et al. 2000). The human HRG gene is 12 Kbp long and maps 
to chromosome 3q27, and consists of seven exons (protein coding). HRG is 
a multi-domain protein that acts as a regulator of coagulation, fibrinolysis 
and angiogenesis (Jones et al. 2005). HRG has been identified as one of many 
serum proteins biomarkers for breast cancer identification (Schaub et al. 
2009). In a very recent study, HRG RNA was detected and evaluated in breast 
tissue biopsies by RT-PCR, and HRG serum protein was evaluated by EIA 
(Matboli et al. 2014). In this study, the authors showed that HRG RNA 
expression increased in all subtypes of breast cancer, with 71.7% sensitivity 
and 93.3% specificity, while HRG serum protein detected by ELISA had 86.7% 
sensitivity and 80% specificity. These data suggest the prognostic value of 
HRG RNA in breast cancer tissue as a novel breast cancer biomarker. 
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Scope of the thesis 
The global aim of my PhD research and this dissertation was to 
develop novel methods and techniques that can be used for the diagnosis of 
unamplified nucleic acids of infectious diseases and tumors in clinical 
specimens. The two major biological models that were chosen to apply the 
developed diagnostic methods to: were Hepatitis C Virus and tumor 
biomarkers (urinary bladder cancer and breast cancer), respectively. 
The specific aims of the thesis were: 
1. The development of a novel diagnostic assay prototype using
unmodified, negatively charged gold nanoparticles for the direct
detection of unamplified Hepatitis C Virus RNA in clinical serum
specimens.
2. The development of a novel assay using magnetic nanoparticles and
positively charged gold nanoparticles for the direct detection of
unamplified Hepatitis C Virus RNA in clinical serum specimens.
3. The development of unmodified negatively charged gold
nanoparticles and magnetic nanoparticles-based assays for the
detection of selected urinary bladder and breast cancer tumor
markers.
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Abstract 
Background: AuNPs exhibit a unique phenomenon known as Surface 
Plasmon Resonance, which is responsible for their intense red color. This 
color changes to blue upon aggregation of AuNPs. Objective: This work aims 
to develop a rapid, simple and cheap assay for direct detection of 
unamplified HCV RNA extracted from clinical samples using unmodified 
AuNPs. Methods: Serum samples were collected from healthy volunteers (n 
= 45) and chronic HCV patients (n = 30). Extracted RNA, hybridization buffer 
containing PBS, and a primer targeting the 5’UTR of HCV were mixed. The 
mixture was denatured, annealed, and then cooled to room temperature for 
10 min followed by addition of AuNPs. Results: Salt, primer, AuNPs 
concentrations and annealing temperature and time were all optimized. In 
HCV positive specimens, the color of the solution changed from red to blue 
within 1 min. The assay has a sensitivity of 92%, a specificity of 88.9%, and 
detection limit of 50 copies/reaction. Conclusions: To our knowledge, this is 
the first assay that allows the detection of unamplified HCV RNA in clinical 
specimens using unmodified AuNPs. The developed assay is highly sensitive, 
has a turnaround time of 30 min, and eliminates the need for thermal cycling 
and detection instruments.  
Key words: HCV RNA, gold nanoparticles, colorimetric assay. 
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Introduction 
According to the World Health Organization, there are around 200 
million people worldwide infected with hepatitis C virus (HCV), with three to 
four million newly infected patients annually (Who). HCV is a small 
enveloped single-stranded RNA virus that belongs to the Flaviridae family, 
Hepacivirus genus, which comprises a group of highly variable strains or 
isolates. HCV is a blood borne virus and infection has different clinical 
outcomes ranging from acute resolving hepatitis to chronic liver disease, 
including liver cirrhosis and hepatocellular carcinoma (Lauer et al. 2001, 
Higuchi et al. 2002, Strader et al. 2004). The acute viral infection resolves in 
15% of infected patients but progresses in 85% of patients to chronic 
infection (Marcellin. 1999).  
Currently HCV is detected using immuno-assays and confirmed by 
molecular assays. Immuno-assays such as enzyme linked immuno-assays 
(EIAs) and recombinant immune blot assays (RIBA) are used for detection of 
anti-HCV antibodies (Sarrazin 2004). Conventional RT-PCR is used for 
qualitative detection of HCV RNA while quantitative detection is achieved 
using real-time RT-PCR and/or branched DNA-based assays (Scott et al. 
2007). Despite the high sensitivity and specificity of these methods, they are 
time-consuming, labor intensive, expensive, and require specialized 
equipment. Therefore, there is a great need to develop a low-tech assay for 
the direct detection of unamplified HCV RNA with acceptable sensitivity and 
specificity, short turnaround time, and cost-effectiveness. Such an assay 
would be critical to control HCV in developing countries with limited 
resources and high infection rates, such as Egypt. 
Nanoparticles have been recently proposed as promising tools to 
develop the next generation of diagnostic assays. Because of their unique 
properties and ability to interact with biomolecules on one-to-one basis, 
various nanoparticles show great promise to meet the rigorous demands of 
the clinical laboratory for sensitivity and cost-effectiveness, and can be used 
in the future in point-of-care diagnosis (Jain 2005). Gold nanoparticles 
(AuNPs) are spheres with a typical diameter of approximately 2 – 50 nm. 
They exhibit a unique phenomenon known as Surface Plasmon Resonance 
(SPR), which is responsible for their intense red color. This color changes to 
blue upon aggregation of AuNPs (Jain et al. 2006). The addition of salt shields 
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the surface charge on the AuNPs, which are typically negatively charged 
owing to adsorbed negatively charged citrate ions on their surfaces, leading 
to aggregation of AuNPs and red-to-blue color shift (Li et al. 2004a). SPR is 
also responsible for the large absorption and scattering cross-sections of 
AuNPs which are 4-5 orders of magnitude larger than those of conventional 
dyes (Huang et al. 2007). These unique optical properties have allowed the 
use of AuNPs in simple and rapid colorimetric assays for clinical diagnosis 
offering higher sensitivity and specificity than current detection techniques 
(Li et al. 2004a, Radwan et al. 2009) 
Li et al. developed a colorimetric assay using unmodified citrate-
coated AuNPs (Li et al. 2004a, Li et al. 2004b). This method is based on the 
fact that single-stranded DNA (ssDNA) adsorbs on citrate-coated AuNPs. This 
adsorption increases the negative charge on the AuNPs leading to increased 
repulsion between the particles, thus preventing aggregation. The 
adsorption of ssDNA on AuNPs occurs due to the fact that ssDNA can uncoil 
and expose its nitrogenous bases. The attractive electrostatic forces 
between the bases and the AuNPs allow adsorption of the ssDNA. On the 
other hand, double-stranded DNA (dsDNA) does not adsorb on AuNPs due 
to the repulsion between its negatively-charged phosphate backbone and 
the negatively-charged coating of citrate ions on the surfaces of the AuNPs. 
Therefore, when AuNPs are added to a saline solution containing the target 
DNA and its complementary unlabeled primer, AuNPs aggregate (since the 
primers are not free to stabilize the AuNPs) and the solution color changes 
to blue. However, in the absence of the target or the presence of a non-
complementary target, the primers are free to stabilize the AuNPs thus 
preventing their aggregation and the solution color remains red. This 
method has been used to detect single nucleotide polymorphisms in PCR-
amplified genomic DNA extracted from clinical samples (Li et al. 2004b). 
Moreover, based on the same principle, AuNPs are capable of quenching 
fluorescent dyes and this property has been used for detection of synthetic 
HCV sequences with high sensitivity and selectivity (Griffin et al. 2009a, 
Griffin et al. 2009b). In this study, AuNPs-based colorimetric method has 
been used to directly detect unamplified HCV RNA extracted from clinical 
specimens (Figure 1). The colorimetric assay is simple, rapid, and sensitive. 
In addition, the hybridization of the unlabeled probe to the target takes 
place in a separate tube before addition of the AuNPs and therefore allows 
hybridization to take place under the desired optimum conditions without 
affecting the stability of the gold colloid. 
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Figure 1. Schematic diagram of a colorimetric assay based on unmodified AuNPs for 
detection of full length HCV RNA. First, the tertiary structure of the target RNA is 
denatured and the complementary primer hybridizes to the target forming double 
strands. Upon adding AuNPs they will aggregate since there are no free primers to 
stabilize the AuNPs, and the solution color changes from red to blue. In the presence of a 
non-complementary target RNA, the primers will be free to bind and stabilize the AuNPs 
thus preventing their aggregation and the solution color remains red. The figure was 
modified with permission from the American Chemical Society. 
Materials and Methods: 
Synthesis of AuNPs 
A colloidal solution of AuNPs with a diameter of 15 nm ± 2 was 
prepared by citrate reduction of hydrogen tetracloroaurate (III) 
(HAuCl4.3H2O) as described elsewhere (Storhoff et al. 1998). Briefly, the 
reflux system was cleaned by aqua-regia and then rinsed with ultrapure 
water, and blown out with N2. An aqueous solution of HAuCl4.3H2O (1 mM, 
100 mL) was brought to reflux while stirring, and then 10 mL of 1 % tri-
sodium citrate (38.8 mM) were added quickly. This resulted in consequent 
change in solution color from yellow to clear to black to purple to deep red. 
Afterwards, the solution was refluxed for an additional 15 minutes and then 
allowed to cool to room temperature. The colloidal solution was then 
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filtered through 0.45 µm acetate filter, and transferred into a clean storage 
glass bottle.  
Characterization of AuNPs 
Size and distribution of the prepared AuNPs were characterized 
using field emission scanning electron microscopy (Model: Leo Supra 55). 
One drop of the AuNPs solution was added onto a silicon slide that was 
allowed to air dry before examination. The λmax for AuNPs was measured 
using UV spectrophotometer (Jenway 6800). The concentration of the 
prepared AuNPs was calculated as described previously (Liu et al. 2007). 
Serum Samples 
Seventy five serum samples were collected from healthy volunteers 
(n = 45) and chronic HCV patients (n = 30). All samples were negative for 
hepatitis B surface antigen and hepatitis B antibody. All positive samples 
have elevated ALT and AST levels. Rapid HCV test was performed on all the 
samples. Viral load of HCV positive samples was determined by real-time 
PCR (Artus kit; Qiagen). 
HCV RNA Extraction 
Extraction of RNA from serum samples was assessed using three 
different kits: 1) QI-Amp Viral RNA kit (Qiagen; Cat. No. 52904), 2) Absolute 
RNA Miniprep Kit (Stratagene; Cat. No. 400800) according to standard 
manufacturer’s instructions, and 3) SV total RNA isolation system 
(Promega; Cat. No. Z3100) according to the modified manufacturer’s 
protocol for HCV RNA isolation (Paul Otto et al. 1998).  Cell free DNA may 
fragment and may interfere with the assay. These fragments lead to false 
negative results due to their adsorption onto the AuNPs. Therefore, the 
samples were treated with DNase to exclude cell-free DNA and/or genomic 
DNA in the sample. Qiagen viral RNA extraction kit as stated in the kit’s 
instruction manual does not guarantee the absence of DNA within the final 
RNA eluted. Using this kit, we obtained false negative results with all 
samples, even at very high viral titers. The Stratagene total RNA kit and 
Promega RNA extraction kit both include a DNase treatment step. 
Reproducible results were obtained with Stratagene and Promega kits. 
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RT-PCR and Real Time RT-PCR 
Amplification of RNA was done by using Qiagen one step RT-PCR 
enzyme mix (Cat. Number 210210) using primers targeting the 5’UTR region, 
forward primer: 5'GTGAGGAACTACTGTCTTCACG'3, and the reverse primer 
5'ACTCGCAGGCACCCTATCAGG'3. The thermal cycling protocol was 50◦ C for 
30 min (reverse transcriptase reaction), 95◦ C for 15 min (Taq activation), 
and 40 cycles of 1 min at 95◦ C, 1 min at 55◦ C, and 1 min at 72◦ C; 10 min at 
72◦C, and then held at 4◦C yielding a product of 265 bp. Real-time RT-PCR 
was done by AgPath ID One Step RT-PCR kit (cat # AM1005; Ambion) where 
8 µL of the sample were taken and completed to 10 µL with ultra-pure water. 
Amplification was done using a Stratagene Mx3005P.  
Colorimetric AuNPs Assay for Detecting Full Length 
HCV RNA in Clinical Samples 
One primer targeting 5’UTR of HCV RNA was added to 10 mM 
phosphate buffer saline solution (PBS, pH = 7.0; hybridization buffer). 
Different concentrations of NaCl in PBS buffer and primer concentrations 
were tested to determine the optimum concentrations for performing the 
assay. Hybridization buffer was prepared using 0.53 M NaCl and 6.66 µM 
(6.6 pmol/µL) primer. Different volumes of the AuNPs were tested, and 10 
µL of the prepared AuNPs (10 nM) was selected for use in the final assay. As 
for the primer used in the assay, two primers were tested, both targeting 
the HCV RNA 5’UTR. The first primer was 22 nucleotides long and the second 
one was 27 nucleotides long. The second primer was finally used in this study 
due to its high specificity to all HCV genotypes and subtypes. In addition, it 
is not complementary to any human mRNAs as verified by blasting the 
primer using NCBI database. 
The assay was performed as follows, 7 µL of the extracted RNA were 
placed in a sterile PCR tube and 3 µL of the hybridization buffer were added 
and mixed well (final concentration of the primer and NaCl after addition of 
AuNPs was 1 µM and 0.08 M, respectively). The mixture was then denatured 
at 95°C for 30 seconds, and annealed at 59°C for 30 seconds and then cooled 
to room temperature for 10 minutes. 10 µL of colloidal AuNPs were then 
added to the mixture, and the color was observed within one minute. For a 
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permanent record of the results, one µL of the final mixture was spotted 
onto a silica plate.   
 Detection Limit Measurements 
HCV positive samples with known viral load, as determined by real-
time PCR, were used to determine the detection limit of the colorimetric 
assay. Serial dilutions of the sample (25-2000 HCV RNA copies) were tested 
using the developed method to determine the detection limit of the assay.  
 Results 
 Size Distribution and Surface Plasmon Band of the 
Prepared AuNPs 
Scanning electron microscope image of AuNPs (Figure 2) was 
analyzed using the Image 1.41J software package (Wayne Rasband, National 
Institutes of health, USA. Http//: rsb.info.nih.gov/ij/Java1.6.0_05). The 
AuNPs were well dispersed as shown in figure 2 and the mean diameter was 
found to be 15 nm (Figure 3). The absorption spectrum of the prepared 
AuNPs displayed a single peak in the visible region with λmax at 518-520 nm.  
 
Figure 2. Scanning electron monographs of the prepared AuNPs. One drop of AuNPs was 
placed on silicon slide and left to dry then examined using field emission scanning 
electron microscopy (Model: Leo Supra 55). 
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Figure 3.  Analysis of the AuNPs size distribution. The scanning electron microscope image 
in Figure 2 was analyzed by Image J 1.4 software Wayne Rasband, National Institutes of 
Health, USA. Http:// rsb.info.nih.gov/ij/java 1.6.0_05. 
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Suitability of RNA Extraction Method 
Serum samples may contain some lymphocytes, which contain 
human mRNA or genomic DNA. Moreover, serum also contains cell-free 
DNA, and nucleoproteins (Sisco 2001). Cell free DNA may fragment and may 
interfere with the assay. These fragments lead to false negative results due 
to their adsorption onto the AuNPs. Therefore, the samples were treated 
with DNase to exclude cell-free DNA and/or genomic DNA in the sample. 
Qiagen viral RNA extraction kit as stated in the kit’s instruction manual does 
not guarantee the absence of DNA within the final RNA eluted. Using this kit, 
we obtained false negative results with all samples, even at very high viral 
titers. The Stratagene total RNA kit and Promega RNA extraction kit both 
include a DNase treatment step. Reproducible results were obtained with 
Stratagene and Promega kits. 
Colorimetric AuNPs Assay: Development & 
Optimization 
The color of AuNPs colloidal solution is affected by four main factors 
which should be adequately optimized for best results. These are 
concentrations of NaCl, AuNPs, and primer used, and the assay temperature. 
AuNPs were prepared using the citrate reduction method which 
produces negatively charged nanoparticles due to citrate coating on their 
surfaces. This negative charge prevents their aggregation and a red color is 
obtained. Salt induces aggregation leading to a red-to-blue shift in solution 
color. The optimum final concentration of NaCl used was 0.08 M, which was 
sufficient for aggregation of AuNPs and visual detection of the color change, 
and at the same time, sufficient for proper annealing of the primer to its 
target.   
Although ssDNA primers adsorb on AuNPs and prevent their 
aggregation, the concentration of the primers should be optimized. This is 
because, in the absence of the target, a very low primer concentration will 
not be sufficient to prevent aggregation leading to a false positive result. On 
the other hand, in the presence of the target, a very high primer 
concentration will prevent aggregation leading to a false negative result. In 
this study, at a final salt concentration of 0.08 M, a primer concentration less 
than 0.2 µM was unable to prevent aggregation of 10 nM 15 nm AuNPs in 
Direct Detection of Unamplified Hepatitis C Virus RNA Using Unmodified 
Gold Nanoparticles 
Page 51 
the absence of the target. On the other hand, a final primer concentration 
more than 3 µM was too high for any aggregation to occur in the presence 
of the target. Consequently, the optimal primer concentration was found to 
be 1 µM in the total assay volume.  
The concentration of 15-nm AuNPs used in the assay was 10 nM in 
a total assay volume of 20 µL. This concentration is sufficient for visual 
detection of the color change, together with the primer and salt 
concentrations discussed above. Change in solution color was not clear and 
false results were obtained when lower concentrations of AuNPs were used.  
Performing the assay without heating (that is essential for RNA 
denaturation and annealing of primers) lead to irreproducible results for 
most of the samples (positive and negative). Consequently, the denaturation 
and annealing steps were deemed necessary before the addition of the 
AuNPs to increase the specificity of the assay. It should be noted that the 
addition of AuNPs directly after removal of the tubes from the thermal cycler 
(while the tubes are still hot), resulted in false positive results. Therefore, 
the mixture must stand at room temperature for 10 to 15 minutes prior to 
addition of AuNPs in order to obtain reproducible results. Increasing the 
time of the denaturation and annealing steps also increases the percentage 
of false positive results. In our opinion, increasing the time of denaturation 
and annealing might increase the probability of the primer annealing non-
specifically to some escaped nucleic acids other than HCV RNA that may be 
found in the nucleoprotein complexes in the serum.  
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Figure 4. Extinction spectra of positive and negative samples. The absorption spectra of 
positive sample (aggregated AuNPs, black) and negative sample (non- aggregated AuNPs, 
red). Note the red shift and broadening of the peak of the positive sample due to 
aggregation of AuNPs. For the negative sample, the λmax was around 518-520 nm. 
Figure 5. Colorimetric HCV RNA assay using unmodified AuNPs. Each tube contains 7 µL 
sample, 1 µM primer and 0.08 M NaCl. The samples were denatured at 95°C for 30 
seconds and annealed at 59°C for 30 seconds and then 10 µL of 15 nm AuNPs was added 
after cooling the mixture at room temperature for 10 minutes. The photographs were 
taken after 1 minute from the addition of the AuNPs. (a) HCV RNA negative samples and 
(b) HCV RNA positive samples. Note the change in color from red to blue in the positive 
samples.  
A B 
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In summary, after adding the hybridization buffer to the extracted 
RNA, the mixture was subjected to denaturation at 95°C for 30 seconds, 
annealing at 59°C for 30 seconds, and then cooling to room temperature 
before the addition of the AuNPs. The change in color was visualized within 
only one minute. Also, change in the AuNPs absorption spectra was 
measured (Figure 4).  28 out of 30 HCV positive samples gave a blue color 
and 40 out of 45 HCV negative samples gave a red color (Figure 5). Based on 
these results, the assay has a sensitivity of 92% and a specificity of 88.9%.   
Real-time RT-PCR was used to calculate the HCV viral load in clinical 
specimens that ranged from 43 IU/mL to 12,000 IU/mL. Serial dilutions of 
the HCV RNA (25–2000 HCV RNA copies) were prepared and assayed using 
the AuNPs as described above. The assay was capable of detecting 50 HCV 
copies/reaction.      
Conclusions 
A colorimetric assay has been developed using unmodified AuNPs 
for the direct detection of unamplified HCV RNA in biological fluids without 
the need for RNA amplification. The assay has a detection limit of 50 copies 
per reaction. The detection limit of the developed assay is better than that 
of the commercially available HCV core antigen test that detects HCV RNA 
levels above 20,000 IU/mL (one IU is typically equivalent to 3-5 copies) 
(Seme et al. 2005). The developed assay may be applied for tracking HCV 
replication even at low viral titers. The developed assay has several 
advantages including acceptable sensitivity, specificity, short turnaround 
time, and cost effectiveness. The cost of 1 gram of gold chloride is about 200 
Euros that is enough to prepare 1 liter of 15 nm gold nanoparticles where 
only 10 µL are needed per assay. Moreover, the use of AuNPs eliminates the 
need for expensive detection instrumentation. Furthermore, there is no 
need for functionalization of the AuNPs, the primer or the target. HCV RNA 
extraction is now easy and takes less than 20 min using commercial kits that 
are based on silica column extraction, magnetic beads, or organic extraction. 
The cost varies between kits but generally it is between 100-200 Euros for 
50 extractions.  
The detection limit of the proposed assay could be improved by 
increasing the starting serum volume used for RNA extraction. Moreover, it 
could be further developed into quantitative tests by spectrophotmetric 
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quantification of the resulting blue color against a standard curve or 
developing a Fluorimetric version of the test by utilization of the size and 
distance nanoparticles surface energy transfer (NSET) properties of AuNPs. 
Also, this method may be further developed for detection of SNPs by 
manipulating the annealing temperature of the primers. This may have great 
implications for HCV genotyping, sub-typing, and monitoring of viral factors 
that have been correlated to patient’s response to interferon therapy (El 
Awady et al. 2009). To our knowledge, this is the first study done using 
unmodified AuNPs for direct detection of unamplified HCV RNA in clinical 
specimens. Upon further developments and optimization, the assay may 
soon compete with commercial immunoassays and RT-PCR methods as 
routine tests for management of HCV patients. 
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Abstract 
Background: The unique properties of metallic nanoparticles have 
allowed their utilization in bio-sensing applications. A novel assay for the 
detection of Hepatitis C Virus (HCV) RNA in serum specimens has been 
developed using magnetic nanoparticles and unmodified cationic gold 
nanoparticles (AuNPs). 
Methods: HCV RNA was extracted using magnetic nanoparticles 
functionalized with an oligonucleotide specific to HCV RNA. Extracted RNA is 
reacted with oligonucleotide sequence specific for HCV RNA in presence of 
unmodified cationic AuNPs. In positive samples, AuNPs are aligned onto the 
phosphate backbone of the RNA and their aggregation changes the solution 
color from red to blue. In the absence of target, solution colour remains 
red.The assay has been tested on 50 serum clinical samples (25HCV positive 
and 25 controls).  
Results: The dual nanoparticles assay detected HCV RNA in serum 
and generated comparable results to real-time PCR. The assay had specificity 
and a sensitivity of 96% and 96.5%; respectively, and a detection limit of 15 
IU/ml. 
Conclusions: The developed colorimetric dual nanoparticles HCV 
RNA assay is simple and inexpensive and can be used for rapid detection of 
unamplified HCV RNA in serum. Similar sensing platforms can be developed 
to detect other nucleic acid targets. 
Keywords: Cationic AuNPs; Hepatitis C Virus (HCV); magnetic 
nanoparticles; nucleic acid Tests (NAT); Qualitative HCV RNA assay. 
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Introduction 
Hepatitis C virus (HCV) is a major global health problems it infects 
about170 million worldwide, with about 3-4 million new infections annually 
(Lavanchy 2009, Miller et al. 2010, Negro et al. 2011, Previsani Nicoletta et 
al. 2013, Who 2011). A variety of molecular assays are available for detection 
of HCV RNA in patients’ blood. These tests can be based on target 
amplifications e.g. qualitative nested reverse transcription polymerase chain 
reaction (RT-PCR), transcription mediated amplification (TMA), and 
quantitative real-time RT-PCR. Signal amplification-based methods are also 
available such as quantitative branched-chain DNA amplification (Scott et al. 
2007). Although these tests have high sensitivity and specificity, they are 
time consuming, labor intensive, expensive, and require specialized 
equipment and relatively sophisticated laboratory infrastructure. Therefore, 
the development of novel diagnostic assays that are simple, rapid, sensitive, 
specific and most importantly cost-effective is urgently needed to control 
HCV in developing countries with limited resources. 
Gold nanoparticles (AuNPs) are among the most promising 
nanostructures which could be employed in diagnostic assays. Owing to 
their Surface Plasmon Resonance (SPR), AuNPs exhibit intense absorbance 
and scattering properties. SPR refers to the collective oscillation of the free 
electrons on the surface of AuNPs, when they are hit by light. The resonance 
frequency lies in the visible portion of the electromagnetic spectrum, and 
thus a colloidal solution of AuNPs (around 20 nm in diameter) would appear 
with an intense red color and will have absorbance maximum around 520 
nm (Radwan et al. 2009), this value is affected by multiple factors including 
AuNPs’ particle size; inter particle distance, and the ionic strength and 
refractive index of the medium. When AuNPs come close together e.g. due 
electrostatic attraction by another moiety, or due to alteration of medium 
ionic strength, Plasmon-Plasmon coupling occurs and a shift in the 
absorbance peak maximum to a longer wavelength and a change in solution 
color from red to blue (Radwan et al. 2009, Larguinho et al. 2012, Kumar et 
al. 2013). AuNPs can be conjugated to bio-molecules (such as proteins, 
antibodies, and nucleic acids) through electrostatic interactions to be 
employed in various biological assays (Radwan et al. 2009). 
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The signal generated in AuNPs-based molecular diagnostic assays 
can be detected by various strategies including colorimetric, scanometric, 
light-scattering, electrochemical and electrical, quartz-crystal microbalance, 
and Nanometal Surface Energy Transfer (NSET) (Ray et al. 2006, Griffin et al. 
2009b), surface enhanced Raman scattering (SERS) and laser diffraction 
strategies (Radwan et al. 2009). AuNPs colorimetric methods are quite 
attractive in diagnostic applications and, usually employ negatively charged 
particles, and can be further categorized into cross-linking (Storhoff et al. 
1998, Storhoff et al. 2004) (utilizing two oligonucleotide-functionalized 
AuNPs probes), non-cross-linking (Conde et al. , Huber et al. 2004, Baptista 
et al. 2005, Costa et al. 2009) [one probe], and non-functionalized [no 
probes] AuNPs (Li et al. 2004a, Li et al. 2004b, Shawky et al. 2010). 
Positively charged (cationic) un-functionalized AuNPs were also 
explored for utility in diagnostic molecular assays. Sun et al (Sun et al. 2005) 
developed a microarray assay (solid support) for gene expression analysis 
using cationic AuNPs, while Hsiao et al (Hsiao et al. 2009)utilized them for 
the determination of DNA microarray chip quality prior to use. He et al 
developed a calorimetric assay for the detection of HIV in clinical specimens 
using gold nanorods and a label-free probe DNA (He et al. 2008).  
In this study, we report for the first time the development of a two 
metallic nanoparticles based colorimetric platform (solution phase) which 
employs non-functionalized cationic AuNPs for the direct detection of 
unamplified HCV RNA extracted from serum specimens. The cationic AuNPs 
bind to the negatively charged phosphate backbone of nucleic acids 
extracted from patient serum. The cationic AuNPs align closely along these 
molecules and thus color change from red to blue. In the absence of the 
target, the positively-charged AuNPs repel each other and the solution color 
remains red. Prior to detection by cationic AuNPs, specific capturing of HCV 
RNA in serum was achieved using functionalized magnetic nanoparticles. 
The principle of the assay is shown in Figure 1. This method is simple, rapid, 
highly sensitive, specific and inexpensive and can replace the currently used 
NATs for the extraction and detection of HCV RNA. Also, the proposed assay 
could be expanded to be used in extraction and detection of other nucleic 
acids targets. 
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Figure 1.The principle of the developed AuNPs-based assay. HCV virions are first lysed 
with RNA lysis buffer, and then proteins are digested with proteinase K (steps 1& 2 
respectively). In step 3, HCV RNA is captured with magnetic nanoparticles conjugated to 
oligonucleotide specific to HCV RNA. The captured RNA is then was heated and eluted 
(step 5) for purification. The last step is the addition of AuNPs and phosphate buffer to 
the purified RNA and the color of the tube was observed within 5 min. In the presence of 
HCV RNA target, alignment of the positively charged AuNPs onto the negatively charged 
phosphate backbone of HCV RNA occurred leading to nanoparticles aggregation and 
solution color changed from red to blue. On the other hand, in case of negative samples, 
no nucleic acid was present for alignment of the AuNPs and thus nanoparticles remained 
separated from each other due to repulsion between their positive charges and the 
solution color remained red.  
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Materials and Methods: 
Iron oxide magnetic nanoparticles: synthesis and 
functionalization 
HCV RNA was extracted using homemade magnetic nanoparticles 
conjugated to an oligonucleotide specific to the 5’untranslated region of 
HCV RNA. First, 90 nm magnetic nanoparticles functionalized with amino 
groups were synthesized as described elsewhere (Kouassi et al. 2005, 
Kouassi et al. 2006). Magnetic nanoparticles synthesized by co-
precipitation of ferric and ferrous chloride. Briefly, FeCl2 and FeCl3(1:2) were 
mixed with deionized water and then mixed with 10 wt.% of amino propyl 
tri-ethoxysilane (APES) with stirring and heating at 80°C.After 5 minutes, 
NaOH was added drop-wise to the mixture and pH adjusted to 10. Heating 
was turned off and the mixture stirred for 20 h with nitrogen gas flow. 
Washing was done with ethyl alcohol (70%) and deionized water and the 
particles were removed with a magnet and dried in vacuum oven at 50°C.  
Characterization of Magnetic Nanoparticles (MNP)  
The size and the morphology of the prepared magnetic 
nanoparticles were characterized by scanning electron microscope (SEM, 
LEO SUPRA 55; Carl Zeiss AG, Oberkochen, Germany). While, Fourier 
transform infrared spectroscopy (FT-IR) was used to record the IR spectra of 
the particles using potassium bromide (KBr) pellet technique. 
Conjugation of HCV specific probe to the amino 
functionalized MNP 
The prepared magnetic nanoparticles were conjugated to a 
synthetic HCV RNA specific probe using a hetero-bi-functional cross-linker 
(3-maleimidobenzoic acid N-hydroxyl succinimide, MBS), which has NHS 
ester at one end (which reacts with primary amine groups forming stable 
amide bond) and a maleimide group at the other end (which reacts with 
sulfhydryl groups forming stable thioether linkage).  
For functionalization of the nanoparticles, the disulfide labeled 
probe was prepared as previously described (Hill et al. 2006, Rosi et al. 
2006). Briefly, disulfide cleavage of the probe was done by lyophilization of 
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10 nmol of the probe and then re-suspended in 100 µL of 0.1 M dithiothrietol 
prepared in disulfide cleavage buffer (170 mM phosphate buffer, pH= 8). The 
solution was wrapped in foil and allowed to stand at room temperature for 
3 h with occasional vortexing. Desalting of the freshly cleaved probe was 
done using Nap-5 column (illustra NAP-5, GE Healthcare) according to the 
manufacturer’s instructions. The amine functionalized magnetic 
nanoparticles were washed twice with di-methyl sulfoxide (DMSO), then 
MBS cross linker dissolved in DMSO was added to the nanoparticles The 
mixture was mixed on a roller shaker for 1 hat room temperature. Then, the 
nanoparticles were washed twice with DMSO followed by coupling buffer 
(100 mM phosphate buffer and 0.2 M NaCl, pH= 7) twice. The particles were 
suspended again in coupling buffer and the cleaved probe added to the 
suspended particles and allowed to react on a roller shaker overnight. 
Finally, the supernatant was removed and the magnetic nanoparticles 
functionalized with HCV RNA specific probe were re-suspended in storage 
buffer (10 mM phosphate buffer, 0.1 M NaCl, pH= 7.4).  
Synthesis of Positively Charged AuNPs 
Positively charged spherical particles were synthesized as 
mentioned elsewhere with slight modifications (Huang 2006, Huang et al. 
2007). Briefly, the seed solution was prepared by reducing HAuCl4 (2.5 ml of 
0.001 M HAuCl4), in presence of CTAB (7.5 mL of 0.2 M), with ice-cold NaBH4 
(600 µL; 0.01 M). The vials were then shaken vigorously (about 2 min) to 
produce brown seed suspensions. The seed (80 μL) was then added to the 
centre of a solution containing HAuCl4 (50 mL of 0.001 M HAuCl4), 50 mLof0.2 
M CTAB, AgNO3 (1.5 mL of 0.004 M AgNO3) and ascorbic acid (700 μL of 
0.0788 M). The mixture was stirred for about 24 hours to produce the 
positively charged gold nanoparticles. 
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Characterization of synthesized AuNPs 
The absorbance spectrum and concentration of the positively 
charged particles was determined using UV spectrophotometer (Jenway 
6800) as previously reported (Link et al. 1999, Jain et al. 2006). The shape, 
size and the charge of the prepared AuNPs were analysed using field 
emission scanning electron microscopy (SEM, LEO SUPRA 55; Carl Zeiss AG, 
Oberkochen, Germany) and zeta sizer (Malvern Instrument Ltd., Zeta sizer 
Nano series, UK); respectively. For the SEM analysis, 5 µL of the synthesized 
AuNPs were placed on silicon wafer and allowed to air dry prior to 
examination. 
Serum specimens 
Serum samples were collected from healthy volunteers (n= 25), who 
have tested negative for HCV antibodies, and from chronic HCV patients (n= 
25). Rapid HCV test was performed on all the samples and positive HCV 
samples tested by real time RT-PCR. All positive samples had elevated ALT 
and AST levels. All samples were negative for hepatitis B surface antigen and 
hepatitis B antibody. HCV standards were included in the study with 
different concentrations. Each serum sample was divided into two portions 
one extracted by SV total RNA isolation system (Promega, cat. No. Z3100) 
following the modified protocol for HCV RNA isolation (Paul Otto et al. 1998) 
and the second portion was extracted using the functionalized magnetic 
nanoparticles prepared as described below. The RNA isolation using the 
functionalized magnetic nanoparticles was repeated twice by 2 different 
persons. 
Real-time RT-PCR 
Real-time RT-PCR was performed using AgPath ID One Step RT-PCR 
kit (cat # AM1005; Ambion) according to manufacturer’s protocol for all the 
samples under study (positive and negative samples), and for the HCV 
standards included in the Real Time PCR kit. To 16.5 µL master mix, 8.5 µL of 
the extracted HCV RNA was added and amplification was performed using 
Stratagene  (Mx3005P) under the following cycling conditions: 1 cycle of 
45°C for 10 min, 1 cycle of 95°C for 10 min followed by 45 cycles of 95°C for 
15s and 60°C for 45s. 
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Colorimetric two nanoparticles HCV assay:  
ADNA sequence specific for HCV RNA was synthesized and 
conjugated to magnetic nanoparticles and used to capture HCV RNA after 
virion lysis, digestion and precipitation of the proteins in patient sera.In a 1.5 
mL micro-centrifuge tube, 100 µL of the magnetic nanoparticles conjugated 
to HCV specific probe was washed twice with the assay buffer (10 mM 
phosphate buffer, 150 mM sodium chloride, pH= 7.4) and then re-suspended 
in 50 µL assay buffer. In another 1.5 mL micro-centrifuge tube, 200 µL of 
patient serum was added to 200 µL of lysis buffer to break down the viral 
envelope. After mixing by inversion, 50 µL proteinase K was added to digest 
the serum proteins and left to incubate for 10 min. Then, the mixture was 
centrifuged for 10 min at 21913 x g and the supernatant was taken and 
mixed with 300 µl of iso-propanol. Then, the re-suspended magnetic 
nanoparticles were added to the previous mixture and heated at 90ºC for 2 
min to denature the target RNA. The mixture was shaken at a temperature 
~15°C below the melting point of the conjugated probe for 45 min. Then, the 
tubes were placed on magnet until all solutions were clear and the 
supernatant was removed. Then, the particles were washed twice with 
washing buffer (60 mM potassium acetate, 10 mM Tris-HCl, 60% ethanol, 
pH=7.5). Supernatant was removed between each wash with the help of 
magnet. Elution was done by adding 50 μL DEPEC –water, and heated at 
95ºC for 2 min. The tubes were placed on magnet until all solutions were 
clear and the eluted HCV RNA was transferred to new RNase free tube. The 
extracted HCV RNA was then assayed using the cationic AuNPs assay as 
described below. 
To 5 μL of the extracted HCV RNA, 5μL of 2M phosphate buffer was 
added followed by 30 μL of the positively charged AuNPs. The sample was 
mixed by pipetting and the color of the solution was observed within 5 min. 
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Results: 
Characterization of magnetic nanoparticles  
The magnetic nanoparticles were well dispersed and the majority of 
the measured nanoparticles have a mean diameter of 90 nm as analyzed by 
scanning electron microscope (Figure 2A). The magnetic nanoparticles were 
functionalized by amino groups through their reaction with 3- aminopropyl 
tri-ethoxysilane (APTES) in a silanization reaction which includes hydrolysis 
and condensation steps (Mikhaylova et al. 2004, Yamaura et al. 2004a, Yang 
et al. 2009a). The FT-IR spectra (Figure2B) of the functionalized magnetic 
nanoparticles confirmed the synthesis and the functionalization procedures. 
The band at 583cm-1 corresponds to the Fe-O bond, the one at 1050 cm-1 
and 1380 cm-1 corresponds to the vibrations of SiOCH2structure and Si-CH2 
scissoring vibrations respectively, while the N-H bending mode and 
stretching vibrations of the free amino groups are appeared at bands 1625 
cm-1 and 3436 cm-1 respectively. Also, the anchored propyl group of the 
APTES is present at band 2923 cm-1. 
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Figure 2. (A) Scanning Electron Microscope image (SEM) of the prepared magnetic 
nanoparticles. (B) FT-IR spectra of the prepared magnetic nanoparticles functionalized 
with amino Propyl tri-ethoxysilane (APES). The peaks showed by the arrows are described 
in the text. 
Characterization of synthesized AuNPs 
UV-Vis spectrum was performed for the prepared AuNPs. The 
spectrum shows a λmax at 531 nm characteristic of spherical AuNPs with 
average diameter of about 46.43 nm and a positive charge of +52.1 mv have 
been confirmed by the zeta sizer analysis (Figure 3). 
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Figure 3.Analysis of cationic AuNPs size (A) and charge (B) using zeta sizer. 
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Detection of HCV RNA in Serum Using Real-time RT-
PCR and Two Nanoparticles HCV Assay 
Fifty serum samples were used in this study; 25 HCV positive and 
25samples from healthy individuals. All the samples were subjected to 
extraction by SV total RNA isolation kit. Extracted HCV RNA was detected 
and quantified using real-time RT-PCR as a standard method for HCV RNA 
detection.  
The extracted RNA was also assayed using the developed two 
nanoparticles based assay. The color of the AuNPs colloidal solution of the 
negative samples remained red which indicates absence of target HCV RNA 
in the sample. On the other hand, the presence of HCV RNA in positive 
samples led to aggregation of the AuNPs and the color changed from red to 
blue (Figure 4). The intensity of the blue color correlated to the HCV viral 
load as quantified by real-time RT-PCR. Of the 25 HCV positive samples, 23 
samples gave blue color which indicated the presence of the HCV RNA, while 
no change in color occurred in 2 samples (false negatives). On the other 
hand, 22 out of 25 negative samples gave red color which indicates the 
absence of HCV RNA in addition to any other nucleic acid, which reflected 
high purity of the sample and efficiency of HCV RNA extraction using the 
magnetic nanoparticles. Only three HCV negative samples gave blue color 
(false positive). The sensitivity and specificity of the assay were 96% and 
96.5%; respectively. The negative predictive and positive predictive values 
were 91.6% and 88.5% respectively, while the assay accuracy was 90%. 
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Figure 4. Detection of HCV RNA extracted from serum using the developed two metallic 
nanoparticles assay. In the absence of HCV RNA, the cationic AuNPs are repelled from 
each other and remain suspended in solution which retains its red color (left tube). On the 
other hand, in the presence of HCV RNA, direct alignment of the cationic AuNPs onto the 
negatively charged phosphate backbone of HCV RNA occurs, leading to change in the 
colour solution from red to blue (other two tubes). The intensity of blue colour is 
proportional to the HCV viral load. 
It is important to note that the same principle can be used in 
extraction and purification of any other nucleic acid and/or protein by simply 
replacing the HCV RNA specific probe with the other target specific molecule 
(e.g. antibodies, lectins, aptamers, etc.), therefore the developed HCV RNA 
extraction method by the magnetic probe could be expanded to be used in 
many other targets. The main aim for capturing the HCV RNA is to remove 
other nucleic acids (DNA or RNA) that may interfere with the assay results 
and thus allowing an increase in assay specificity. 
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Discussion and Conclusions 
We report the development of a two nanoparticles assay platform 
for direct detection of unamplified HCV RNA in serum. The assay employed 
magnetic nanoparticles functionalized with oligonucleotide specific for HCV 
RNA for its extraction from serum. Cationic AuNPs were then used to detect 
the presence of HCV RNA by generating a colorimetric signal. In case of 
positive samples, the CTAB capped cationic AuNPsbound to the negatively-
charged phosphate groups of the HCV RNA target (Sun et al. 2005, Jain et al. 
2006). The presence of phosphate buffer in the assay increased the 
aggregation capability of the AuNPs (for only the positive samples) where 
we propose that phosphate ions bound to the aligned cationic AuNPs on HCV 
RNA and then another row of AuNPs attaches to the phosphate ions which 
will be aligned on another phosphate backbone of another RNA molecule 
and so on. So, aggregation occurred by first alignment of AuNPs on 
phosphate backbone of one nucleic acid, which then binds to phosphate ions 
and the latter binds to other AuNPs which then binds to other nucleic acid 
phosphate backbones. Therefore, several layers (1stRNA/AuNPs/Phosphate 
ions/AuNPs/2ndRNA) were formed in the positive samples leading to AuNPs 
aggregation. These layers will result in forming a network of nucleic acid/ 
AuNPs which lead to AuNPs aggregation and change of colour from red to 
blue (Wang et al. 2003, Koyfman et al. 2005). To confirm our hypothesis, 
SEM images were taken for a positive sample (Figure 5A) showing many 
layers of AuNPs aligned on RNA molecules. 
In the absence of HCV RNA (absence of any nucleic acid), the AuNPs 
are far from each other (repulsion between positively-charged particles) and 
thus the solution colour remained red (Figure 4). A SEM image (Figure 5b) 
was taken for a negative sample which shows no aggregation of AuNPs. It is 
important to note that the red colour was stable even when left undisturbed 
for several days. Moreover, the prepared cationic AuNPs are stable for about 
2 years and no change in their colour or charge occurred to the 
nanoparticles. 
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Figure 5. SEM analysis of AuNPs in positive and negative HCV assays. (A) SEM of AuNPs in 
positive HCV sample. AuNPs aggregate on RNA molecules in presence of phosphate 
buffer. (B) SEM of AuNPs in the absence of HCV RNA (no aggregation of AuNPs). 
This study reports for the first time the development of a 
colorimetric solution-phase two nanoparticles assay for direct detection of 
unamplified HCV RNA extracted from clinical specimens. The assay has high 
sensitivity and specificity of >95%, and a detection limit of 15 IU/mL. The 
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turnaround time of the proposed assay is about 75 min (including RNA 
extraction) which is about one third the turnaround time of the standard real 
time PCR method. The assay costs about US$10 per test, which is several 
folds cheaper than that of the real time PCR. Moreover, the test can be 
developed into a quantitative one since the intensity of the blue color 
generated correlated with the HCV viral load as determined by real time RT-
PCR (Figure 4). 
In conclusion, the developed assay is simple (adding cationic AuNPs 
solution to the extracted RNA in presence of phosphate buffer), rapid, 
sensitive, inexpensive, and similar platforms can be used for the detection 
of other RNA and/or DNA targets in solution.  
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4 Development and evaluation of gold nanoparticles 
assays for direct detection of urinary bladder and 
breast cancer biomarkers 
This research has been developed into two papers: 
1- Direct detection of unamplified Hepatoma up Regulated protein RNA in 
urine using Gold Nanoparticles for Bladder Cancer Diagnosis. Sanaa 
Eissa, Sherif M. Shawky, Marwa Matboli, Shymaa Mohamed and Hassan 
M.E. Azzazy. Clinical Biochemistry 2014, 47 (1-2): 104-110. PMID: 
24183881 
2- The prognostic value of Histidine-Rich Glycoprotein RNA in Breast 
Tissue using unmodified Gold nanoparticles assay. Sanna Eissa, Hassan 
Azzazy, Marwa Matboli Sherif M. Shawky, Hebatallah Said, Faten 
Anous. Applied Biochemistry and Biotechnology. 2014 August 2014. 
PMID: 25091325 
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Abstract 
Objective: To develop an unmodified gold nanoparticles-based 
assay for the direct detection of unamplified HURP RNA in urine samples for 
early bladder cancer diagnosis. The second aim is to develop an unmodified 
AuNPs assay for the direct detection of unamplified HRG RNA in breast 
cancer tissues.  
Methods: HURP RNA was extracted from urine samples (50 bladder 
carcinomas, 25 benign bladder lesions, and 25 controls). Also, HRG RNA was 
extracted from breast tissues (60 patients proven to have breast carcinomas, 
30 with benign breast lesions and 30 controls). The extracted RNA for both 
markers was further purified using homemade magnetic nanoparticles 
functionalized with target-specific oligonucleotides. Real-time PCR (RT-PCR) 
was performed on the extracted RNAs before and after the magnetic 
purification step. The developed AuNPs assay was performed on the extra-
purified RNA targets. 
Results: The developed HURP RNA AuNPs assay had a sensitivity and 
specificity of 88.5% and 94%, respectively, with a detection limit of 2.5 
nmol/L. The HRG AuNPs assay had a sensitivity and specificity of 90%, with 
a detection limit of 1.5 nmol/L.  
Conclusion: The developed colorimetric assays for both biomarkers 
are sensitive, specific, simple, rapid and inexpensive. Moreover, the assays 
maybe further developed for the detection of other cancer biomarkers. 
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Introduction 
Hepatoma Up regulated protein (HURP) RNA has been recently 
identified as a powerful biomarker in urine specimens that could be used for 
the early detection of bladder cancer (Kaufman et al. 2009, Eissa et al. 
2014b). On the other hand, histidine-rich glycoprotein (HRG) is considered 
as a serum biomarker for breast cancer detection (Schaub et al. 2009). 
Moreover, HRG RNA has been found to be over-expressed in breast cancer 
tissues in comparison to normal tissues (Matboli et al. 2014). Increasing 
cancer patient survival rates and the prevention of cancer spread among 
high-risk individuals are directly proportional to the early detection of the 
disease and screening, respectively. In the past few years, the field of 
identifying, evaluating and employing novel biomarkers for accurate 
detection of different cancers has evolved rapidly (Choi et al. 2010). 
Meanwhile, advances in the field of nanotechnology as an emerging science 
in the last decade have allowed the development of many nanoparticles-
based assays for direct detection of bio-molecules [RNA, DNA, proteins] (Jain 
2005, Azzazy et al. 2006, Radwan et al. 2009, Alharbi et al. 2014). 
Nanoparticles have been recently proposed as promising tools for the 
development of the next generation of diagnostic assays. Because of their 
unique properties and ability to interact with biomolecules on a one-to-one 
basis, various nanoparticles show great promise to meet the needs of the 
clinical laboratory concerning simplicity, sensitivity, specificity and low cost. 
Information regarding the discovery of cancer biomarkers and the progress 
of nanotechnology in laboratory medicine is examined in this chapter to aid 
in the development of gold nanoparticles-based assays for the detection of 
RNA-based tumor markers in clinical samples from urinary and breast 
cancers. 
Unmodified AuNPs-based colorimetric assays have been developed 
in two independent studies. The first one was for the direct detection of 
HURP RNA in urine samples for bladder cancer diagnosis (Eissa S. et al. 2014), 
while the second (Eissa et al. 2014a) have explored the role of the histidine-
rich glycoprotein (HRG) RNA in tissue biopsies as a promising clinically useful 
biomarker for the prognosis of breast cancer patients. Prior to its detection 
by the unmodified AuNPs, specific capture of the target RNAs (HURP in urine 
samples and HRG RNA in tissues samples) was achieved using magnetic 
nanoparticles functionalized with target-specific probes. The two assays that 
Development and evaluation of gold nanoparticles assays for 
direct detection of urinary bladder and breast cancer biomarkers 
Page 76 
were developed were compared to the conventional RT-PCR and standard 
cytology and cystoscopy methods. Moreover, the use of the proposed assay 
was expanded to the purification and/or detection of other nucleic acids 
targets. In these assays, total RNA was first extracted from the sample, and 
then magnetic nanoparticles functionalized with target specific 
oligonucleotide were added to the extracted RNA to capture the target RNA. 
The captured RNA was then washed and eluted. A portion of the target RNA 
was mixed with hybridization buffer (NaCl and target-specific primers). After 
1 minute for denaturation and annealing, AuNPs were then added and the 
color change was observed within 2 minutes. The assay was based on the 
fact that single stranded DNA (ssDNA) adsorbs to the citrate-coated AuNPs 
through its nitrogenous bases and, thus, stabilizes the AuNPs, thereby 
preventing their salt-induced aggregation. In contrast, double stranded DNA 
(dsDNA) does not adsorb to the surface of the nanoparticles due to the 
repulsion between its negatively charged phosphate backbone and the 
negatively charged surface of the AuNPs (Li et al. 2004a, Li et al. 2004b, Li et 
al. 2005, Li et al. 2007, Shawky et al. 2010). Therefore, when a colloidal 
solution of the AuNPs is added to a saline solution containing ssDNA 
(oligotargeter), the latter is free to stabilize the nanoparticles and prevent 
their aggregation, and the solution remains red. In the presence of a 
complementary target to the oligotargeter, the latter leaves the surface of 
the AuNPs, hybridizes to its target, and the AuNPs aggregate by the action 
of the salt in the solution As a result, the solution turns blue. The principle 
of the assay is summarized in figure 1. 
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Figure 1: Schematic diagram of the developed unmodified AuNPs based assay. After 
extraction of the total RNA in the sample, the target RNA is captured using magnetic 
nanoparticles functionalized with the target probe. The target is then mixed with 
hybridization buffer (NaCl and target specific probe).After denaturation of the target and 
annealing to its specific probe (the straight black and blue lines respectively) AuNPs were 
then added to the mixture and color change was observed within 2 minutes. 
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Materials and methods 
Study Population 
Both studies were approved by Ain Shams University, faculty of 
medicine ethical committee. Samples collection and biopsies was performed 
at Ain Shams University, Faculty of Medicine, Cairo, Egypt. 
4.3.1.1 Urinary Bladder Cancer 
A prospective analysis was performed on 100 Egyptian subjects, 75 
patients were selected from urology department, Ain Shams University, 
Egypt, in addition to 25 healthy normal volunteers as a control group 
between January 2011 and June 2012, after obtaining informed consent. 
Patients presented with hematuria and chronic irritative voiding symptoms 
were included in the study and patients with past history of bladder cancer 
or any other malignancy were excluded from the study. All patients provided 
a single voided urine sample before cystoscopy. Biopsy of any suspicious 
lesion was performed for histo-pathologic examination. Accordingly, the 75 
patients included in the study were classified into malignant and benign 
groups. The malignant group included 50 patients (mean age 59.8 ±9.3 years, 
and range from 37-79 years). Of those patients, 42 were diagnosed by 
histopathology with transitional cell carcinoma (TCC), and 8 with squamous 
cell carcinoma (SCC). Tumor staging and grading was determined according 
to TNM and World Health Organization classification 1973. The benign group 
included 25 patients with benign urological diseases: bilharzial dysplastic 
lesions, renal stone and urethral stricture (mean age 52.88 ± 9.4 years, and 
range from 25-68years). A group of 25 healthy volunteers (mean age 45.44 
± 11.9 years, and range from 28-79 years) recruited from the hospital 
laboratory staff. 
4.3.1.2 Breast Cancer 
A prospective analysis was performed on 120 Egyptian subjects, 90 
patients were selected from General Surgery department, Ain Shams 
University Hospitals, Cairo, Egypt, in the period from November 2008 to June 
2009then was followed up for recurrence till december2013, after obtaining 
informed consent. 
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Sample size (120 subjects: 60 cases and 60 controls) was calculated 
by Epi-info version 6 software using prevalence rate of breast disease: 29%, 
odds ratio of oral contraception: 2, α: 0.05, power: 80% and confidence level: 
95%. Patients presented with breast mass and/or bleeding per nipple were 
included in the study and patients with past history of breast cancer or any 
other malignancy, inflammatory mastitis, chemotherapy or radiotherapy 
were excluded from the study. Tissue specimens were reviewed 
independently by histopathologists to grade and sub-classify the tumors 
based on established criteria. Subsequently, the 90 patients included in the 
study were classified into malignant and benign groups. The malignant group 
included 60 patients (mean age 52.47± 13.2 years, and range from 20-81yrs). 
43 of which were histopathologically diagnosed as invasive duct carcinoma 
(IDC),1 patient with invasive lobular carcinoma (ILC), 9 with mixed invasive 
duct and lobular carcinoma and 7 patients with rare histological types . 
Tumor staging and grading was determined according to TNM and World 
Health Organization classification. The benign group included 30 patients 
with benign breast diseases; (fibro adenoma,) (49.6± 14.11years, and range 
from 20-67yrs).The third study group was represented by 30 healthy 
volunteers who underwent plastic breast reduction surgery (mean age 50.47 
± 11.64 yrs., and range from 36-77yrs) with matching age and sex to the 
patient’ groups. Breast cancer patients were regularly followed up every 6 
months. Local-regional relapses and the subsequent surgery during the 90-
day post-surgery period were considered to be part of the primary 
management and distant recurrence during this time disqualified the patient 
from study. Relapses after 90 days were considered events. Relapses were 
dated and reviewed by two of three medical oncologists. 
Amino functionalized MNP synthesis, functionalization 
and characterization 
Amino functionalized homemade magnetic nanoparticles were 
prepared by chemical co-precipitation method as described previously with 
slight modifications (Kouassi et al. 2005, Kouassi et al. 2006). Briefly, 
ferrous chloride and ferric chloride in a 1/2 molar ratio were mixed with 
deionized water and then mixed with 10wt % of amino-propyl tri-
methoxysilane (APMS) with slight heating. After 5 minutes ammonium 
hydroxide was added drop-wise to the above mixture and the pH adjusted 
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to 12. The heating was turned off and stirring continued for another 30 
minutes. The resulting particles were washed thoroughly with 
ethyl alcohol 70% and deionized water to remove ammonia traces. The 
particles were then removed by a magnet and dried in vacuum oven 
overnight at 50̊ C. Size and morphology of the magnetic nanoparticles were 
characterized by scanning electron microscope (SEM, LEO SUPRA 55; Carl 
Zeiss AG, Oberkochen, Germany). 
Conjugation of HURP and/or HRG RNA specific probes to the amino 
functionalized magnetic nanoparticles was carried out as described 
previously in chapter 3. The conjugation process was based on a hetero bi-
functional cross linker (3- maleimido benzoic acid N-hydroxyl succinimide, 
MBS) that has an NHS ester at one end which reacts with primary amine 
groups on the magnetic nanoparticles forming stable amide bonds, the other 
end has a maleimide group that reacts with sulfhydryl conjugated probes 
forming a stable thioether linkage. 
Synthesis and characterization of Gold Nanoparticles  
Spherical gold colloid was prepared using citrate reduction method 
as described elsewhere (Hill et al. 2006). Briefly, an aqueous solution of 
hydrogen tetra chloroaurate (III) (HAuCl4.3H2O) (1mM) (99.99% Sigma 
Aldrich, Germany) was brought to reflux and stirred followed by a quick 
addition of 1% tri sodium citrate solution. The solution color changed from 
yellow to wine red. The solution was then refluxed for an additional 15 min 
and left to cool at room temperature. The resulting spherical gold 
nanoparticles were filtered using a 0.25 µm syringe filter (Sigma), and 
transferred into a clean storage glass bottle. Size and distribution of the 
morphology of the AuNPs was characterized using field emission scanning 
electron microscopy (Model: Leo Supra 55). One drop of the AuNPs solution 
was added onto a silicon slide that was allowed to air dry before 
examination. The particle mean diameter was measured by dynamic light 
scattering (DLS, Malvern Instruments, UK). The λmax for AuNPs was detected 
by scanning the colloidal AuNPs from 400-700 nm using UV 
spectrophotometer (Jenway 6800).   
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Total RNA extraction 
Total RNA extraction procedures were done at Ain Shams University, 
Faculty of Medicine, laboratories, Cairo, Egypt. The detailed procedures are 
described below. 
4.3.4.1 Urinary Bladder Cancer 
Voided urine samples were obtained before cystoscopy and washed 
in phosphate-buffered saline (PBS, pH 7) and centrifuged at 1000 times 
gravity for 10 minutes. A portion of the pellet was taken for cytology 
examination and another portion was immediately processed for RNA 
extraction using Tri Fast kit (PeQ Lab Biotechnologie GmbH Corporation) 
according to the manufacturer’s instruction (Sambrook J et al. 1989, Eissa et 
al. 2003). The extracted RNA was divided into two parts; the first part was 
used for detection of HURP by RT-PCR; while second part was further 
purified by magnetic nanoparticles.  
4.3.4.2 Breast Cancer 
After primary surgery, a representative part of the tumor tissue was 
immediately frozen and stored at -80 freezer for RNA extraction (Qiagen, 
Hilden, Germany). Total RNA was purified with TriFast™ (PeQ-Lab 
Biotechnologie GmbH Corporation) according to the manufacturer’s 
instructions (Sambrook J et al. 1989, Hummon et al. 2007). 
HURP & HRG RNA purification by MNP functionalized 
by a target specific probe 
Hundred micro-liters of functionalized magnetic nanoparticles was 
taken and washed twice with the assay buffer (10 mM phosphate buffer, 150 
mM sodium chloride, pH= 7.4) and then re-suspended in 50 μL assay buffer 
and mixed well with about 40 μL of the target and heated at 70ºC for 2 min. 
The mixture was shaken for 45 min to allow hydrogen bond formation 
between the immobilized probe and target RNA to achieve proper capture. 
An external magnet was then placed at the bottom of the tube until the 
solutions were clear. The supernatant was then removed and the particles 
were washed twice with washing buffer (60 mM potassium acetate, 10 mM 
Tris-HCl, 60% ethanol, pH=7.5). The supernatant was removed between each 
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wash with the help of a magnet. Elution was done by adding 40 μL deionized 
water, and heated at 95ºC for 2 min. The tubes were placed on magnet until 
all solutions were clear and the eluted target mRNA (HURP or HRG) in the 
supernatant was transferred to new tube. 
RT-PCR for HURP and HRG RNA 
RT-PCR reactions were done in Hybaid thermal cycler (Thermo 
Electron [formerly Hybaid] Waltham, MA) using the Qiagen One Step RT-PCR 
Kit. Hepatoma up regulated (HURP) protein RNA primers were: sense 
primer: 5'-CCCATCTTCCCTTGAGAAAG-’3, antisense primer: 5'-AGG AGA CAT 
CAA GAA CAT GC-'3 (Accession NM_ 001146015). The thermal cycling 
protocol was 42°C for 60 min, 95°C for 15 min, and 30 cycles of 1 min at 94°C, 
1 min at 50ºC, and 1 min at 72ºC, and final extension step at 72ºC for 10 min. 
On the other hand, Histidine-rich glycoprotein (HRG) primers were: sense 
primer: 5'-GATCATCATCATCCCCACAAG-’3, antisense primer: 5'- 
GGGTCACAAGGTCCATAGTC -'3, (accession NM_000412.2) (Sabbatini et 
al. , Koide et al. 1986). The thermal cycling protocol was 50°C for 30 
minutes, 95°C for 15 minutes, and 30 cycles of 1 min at 94°C, 1 min at 50ºC, 
and 1 min at 72ºC, and final extension step at 72ºC for 10 min. 
Amplicons of both targets were run on 2% agarose gel 
electrophoresis. The quality of RNA was checked by amplification of c-DNA 
for β-actin  to ensure successful completion of the c-DNA step using the 
primer pair; sense 5'-AGC GGG AAA TCG TGC GTG -3', and antisense 5'-CAG 
GGT ACA TGG TGC C -3' (Accession NM_ 001017992.2), (Smith et al. 2001). 
The developed colorimetric AuNPs based assay for 
target RNA detection 
One antisense primer (oligotargeter) targeting the purified RNA 
(HURP or HRG) was mixed with a NaCl solution to prepare the hybridization 
buffer. Different salt and primer concentrations were tested to determine 
their optimal concentrations for the assay. The hybridization buffer 
contained NaCl and anti-sense primer with final concentrations of 0.42 M 
and 9 µM, respectively. The assay was done by mixing 5 µL hybridization 
buffer, 5 µL sample RNA and 20 μL AuNPs. The color change was observed 
within 1 min. 
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Detection Limit Measurement 
Serial dilutions of RNA sample of known concentration were tested 
using the AuNPs assay to determine its detection limit. RNA sample of known 
concentration (concentration was measured spectrophotometrically), was 
taken and serial dilutions for the sample were done, and the RNA was 
detected in the above mentioned dilutions using the developed AuNPs 
Statistical Analysis 
Univariate analyses were performed using a Chi square test of association of 
categorical variables. Sensitivity, specificity, positive predictive value (PPV), 
negative predictive value (NPV), and accuracy were calculated according to 
standard statistical methods. All analyses were performed using Statistical 
Package for the Social Sciences software (SPSS Inc., Chicago, IL). 
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Results 
Size Distribution of amine functionalized magnetic 
nanoparticles 
A scanning electron microscope image of the prepared magnetic 
nanoparticles (Figure 2), was analyzed using the 1.41 image J. software 
package (Wayne Rasband, National Institutes of health, USA. 
Http//:rsb.info.nih.gov/ij/Java1.6.0_05). The particles were well dispersed 
and their mean diameter was 95 nm ± 5 nm. The magnetic nanoparticles 
were functionalized by amino groups through the reaction of the 
nanoparticles with 3- aminopropyl tri-methoxysilane (APMS) by a 
silanization reaction (Mikhaylova et al. 2004, Yamaura et al. 2004b, Yang et 
al. 2009b), that includes hydrolysis and condensation steps, the detailed 
reaction can be found in (Yamaura et al. 2004b). 
Figure 2. Scanning electron monograph (SEM) of the prepared magnetic nanoparticles, 
functionalized with amino groups 
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Size distribution and surface Plasmon band of the 
prepared AuNPs 
Figure 3A shows the SEM image of the prepared gold nanoparticles. 
The mean particles diameter of the prepared AuNPs was found to be about 
13 nm± 2 nm (Figure 3B).  Figure 3C shows the absorption spectrum of the 
prepared AuNPs that displayed a single peak in the visible region with a λmax 
at 518-520 nm which is typically the SPR of the AuNPs of this size (Hill et al. 
2006, Rosi et al. 2006). 
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Figure 3. (A) Scanning electron monographs of the prepared AuNPs. (B) Size distribution of 
AuNPs and (C) the absorption spectra of AuNPs showing λmax at 518-520 nm. 
RT-PCR for HURP and HRG 
RT-PCR of HURP and HRG RNA was done as described in the methods 
section. RT-PCR of HURP yielded an amplicon of 258 base pair (Figure 4A), 
while that of HRG yielded an amplicon of 404 bp (Figure 4B). Amplification 
of c-DNA for β-actin yielding an amplicon of 309 bp. Introduction of an 
additional purification step using the functionalized magnetic nanoparticles 
improved the sensitivity of the HURP RT-PCR from 64% to 84%, while the 
HRG RT-PCR sensitivity was improved from 71.7% to 80%. Moreover, the 
specificity of the HURP RT-PCR was improved from 90% to 94% after 
magnetic purification, while no change in specificity occurred in the HRG RT-
PCR. 
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Figure 4. (A) Semi-quantitative RT-PCR of the urinary HURP and beta actin RNA using 
agarose gel electrophoresis that produced bands with 258 and 309 bp respectively. Lane 
1-4: urine from bladder cancer patients, Lanes 5-8 urine from benign genitourinary 
conditions and Lane 9-10: urine from healthy normal individuals. (B) RT PCR analysis for 
Breast tissue HRG showing 309 bp. Lanes 1–4: biopsy from breast cancer patients 
showing positive HRG, Lanes 5-6: biopsy from benign breast conditions showing 
positive beta actin bands and negative HRG. Lanes 7-8: biopsy from normal breast 
showing positive beta actin bands and negative HRG. Lane MW: molecular weight 
ladder standard (100 bp). 
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AuNPs assay: development and optimization 
The color of AuNPs colloidal solution is affected by three main 
factors which should be adequately optimized; those are the concentrations 
of NaCl, AuNPs, and ss DNA (primer) used. The final NaCl concentration was 
0.07 M, while the final primer concentration was 1.5 μM in the total assay 
volume, for 10 nM AuNPs which was sufficient to stabilize the AuNPs and 
prevent their NaCl induced aggregation. The sample was mixed with the 
hybridization buffer and then colloidal solution of AuNPs was added to the 
mixture, and the color change was observed within 1 min. The positive 
samples, had the color changed from red to blue, while, the color remained 
red in the negative samples (Figure 5). 
Figure 5: Unmodified AuNPs assay. The color of the colloidal AuNPs solution changed from 
red to blue within 2 minutes in positive samples (tubes 3-6), while in negative samples 
(tubes 1-2), the AuNPs color solution remains red. 
AuNPs assay: performance characteristics 
HURP RNA was detected in RNA extracted from urine samples by the 
developed AuNPs assay, 45 malignant samples out of 50 were positive, with 
a sensitivity of 90%. On the other hand, all 25 normal samples were negative, 
while 22 out of 25 benign samples were negative and 3 samples were false-
positive. The specificity of the assay was 94%.The lower detection limit of 
the HURP RNA AuNPs assay was 2.4nanomole/L. On the other hand, HRG 
RNA detection in tissues done by the developed AuNPs assay has a sensitivity 
and specificity of 90%, with a detection limit of 1.5 nmol/L. The optimization 
resulted in a reproducible and accurate assay for the direct detection of 
unamplified RNA targets in the samples. 
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Discussion 
Discovery of new tumors biomarkers is a highly dynamic research 
field and aims at achieving highly sensitive and specific biomarkers for early 
cancer diagnostics and prognostics. Advances in genomics, proteomics and 
epigenetics, in addition to cancer cell research, have led to a deluge of novel 
biomarkers for cancer diagnosis and prognosis. However, many of these 
novel biomarkers have not yet been implemented in practice guidelines due 
to the lack of sufficient validation required to attain a significant level of 
evidence (Swellam et al. 2004, Cecchini et al. 2012, Smith et al. 2013, Xylinas 
et al. 2014). The unique properties of the emerging nanoparticles, such as 
gold and magnetic nanoparticles, made them attractive and promising for 
applications in molecular diagnostics, and they are showing great promise in 
the development of assays that are simple, rapid, sensitive, specific and cost-
effective. Moreover, the National Cancer Institute is engaged in efforts to 
harness the power of nanotechnology to radically change cancer diagnosis 
and treatment (Azzazy et al. 2006). The magnetic separation of nucleic acids 
has several advantages compared to other techniques used for the same 
purpose. Nucleic acids can be purified from crude sample materials such as 
blood and tissue homogenates (Thaxton et al. 2005). Magnet particles can 
be removed relatively easily and selectively, even from viscous sample 
suspensions, by adjusting the magnetic properties of the solid materials. In 
fact, magnetic separation is the one of the best attainable method for the 
recovery of small particles (diameter approx. 50–1000nm) in the presence 
of biological debris, and high efficiency magnetic separation can be used for 
large-scale purifications to detect ultra-low concentrations of tissue-based 
genetic biomarkers (Franzreb et al. 2006). This is due to many reasons for 
example, magnetic nanoparticles at this size scale have high surface area so, 
they can capture more target. Also, its surface can be easily modified with 
many capping agents like strepatavidin, amino and thiol groups. Moreover, 
magnetic nanoparticles could be easily separated from the sample after the 
purification and/or the washing steps by simply applying external magnet 
so, separation time is saved, and also effort if compared for example to the 
silica based columns used in purification of nucleic acids that need many 
centrifugation steps throughout the purification steps. 
Magnetic nanoparticles are currently used commercially in nucleic 
acid and proteins purification, and are produced by many reagents 
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companies, such as Invitrogen and Miltenyi Biotec GmbH. However, the 
commercialized particles are expensive, have a low stability, and usually 
tend to aggregate and precipitate. We have succeeded in avoiding these 
drawbacks of the commercial magnetic nanoparticles, as our magnetic 
particles are stable, easy to synthesize, have a mono-distribution, and, most 
important, have a low preparation cost. In the current chapter, we report 
two nanoparticles (magnetic and gold nanoparticles) for the direct detection 
of unamplified HURP and HRG RNA for urinary bladder and breast cancers 
diagnosis and/or prognosis, respectively. The HURP RNA, as a urinary 
bladder cancer biomarker, was detected in urine samples by the developed 
AuNPs-based assay. Moreover, RT-PCR of HURP RNA was performed before 
and after the developed magnetic HURP RNA purification. All the methods 
were compared to the standard cystoscopy and cytology methods, and the 
data is shown in Table 1. The developed AuNPs assay detected HURP RNA in 
90% of the urine samples of malignant cases and in 12% of the benign cases, 
and yielded negative results for the control samples. The combination of the 
developed AuNPs assay with urine cytology improved the sensitivity of urine 
cytology from 64% to 100%, even in low-grade and superficial bladder 
cancer, which confirms the possibility of using the developed assay in the 
early detection of urinary bladder cancer. Also, HURP RNA was detected 
using conventional RT-PCR, with a sensitivity and specificity of 63% and 90%, 
respectively. After the magnetic purification step, the sensitivity and 
specificity of the HURP RT-PCR assay improved to 85% and 94%, respectively. 
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Table 1:   Clinical characteristics of the assay used for detection of urinary HURP RNA and 
cytology in superficial (Stage 0+1) and grade 1 bladder cancer patients. Abbreviations: 
AuNPs: gold nanoparticles, HURP: Hepatoma Up regulated protein, MP: magnetic 
nanoparticles, RT-PCR: reverse transcriptase polymerase chain reaction. 
Parameter Sensitivity Specificity NPV PPV Accuracy 
Bladder cancer group (n=50) 
Cytology 62% 98% 72% 96% 80 
RT-PCR before MP purification 64% 90% 71.4% 86.4% 77% 
RT-PCR after MP purification 84% 94% 85% 93.3% 89% 
HURP by nano assay 90% 94% 90.3% 93.3% 92% 
RT-PCR before MP purification+ 
cytology 
86% 90% 86.5% 89.9% 88% 
RT-PCR  after MP purification 
+cytology 
100% 94% 100% 94.3% 97% 
HURP by nano assay+ cytology 100% 94% 100% 94.3% 97% 
Superficial bladder cancer (stage 0 &1)(n=28) 
Cytology 57.1% 98% 80.3% 94.4% 83.3% 
RT-PCR before MP purification 64% 90% 81.8% 78.2% 80.7% 
RT-PCR after MP purification 82.1% 94% 90.3% 88.4% 93.3% 
HURP by nano assay 89.3% 94% 94% 89.2% 92.3% 
RT-PCR before MP purification+ 
cytology 
89.3% 90% 93.75% 83.3 % 89.7% 
RT-PCR after MP purification 
+cytology 
100% 94% 100% 90.3% 96% 
HURP by nano assay+ cytology 100% 94% 100% 90.3% 96% 
Grade 1 bladder cancer (n=8) 
Cytology 50% 98% 92.4% 80% 91.3% 
RT-PCR before MP purification 62.5% 90% 93.75% 50% 86.2% 
RT-PCR after MP purification 87.5% 94% 97.9% 70% 93.1% 
HURP by nano assay 87.5% 94% 97.9% 70% 93.1% 
RT-PCR before MP purification+ 
cytology 
75% 90% 95.7% 54.5% 87.9% 
RT-PCR after MP purification 
+cytology 
100% 94% 100% 72.7% 94.8% 
HURP by nano assay+ cytology 100% 94% 100% 72.7% 94.8% 
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Meanwhile, HRG RNA was detected in breast tissues of malignant, 
benign and normal individuals using the developed AuNPs assay. The assay 
had a sensitivity and specificity of 90%, with a detection limit of 1.5 nmol/L. 
Moreover, HRG RNA was detected using conventional RT-PCR. The 
sensitivity and specificity of RT-PCR were 71.7% and 93%, respectively. 
Upon the introduction of the magnetic purification before the RT-PCR, the 
sensitivity of the latter increased to 80%, which is still less than the 
proposed AuNPs assay, as shown above. The evaluation and comparison of 
the AuNPs results with RT-PCR and the histopathology finding, in addition 
to its relation to the cancer grade, are summarized in Table 2. As shown 
below in table 2, the developed AuNPs’ assay sensitivity has been increased 
in the three stages and grades of the malignant groups, in addition to the 
different subtypes of the breast cancer. The data obtained in this study, 
may consider HRG RNA expression as an evolving independent biomarker 
prognostic factor for breast cancer that can be detected using the 
developed gold nanoparticles assay. Our results agreed with bioinformatics 
analysis of HRG transcript expression using data from GOBO tool (Ringner 
et al. 2011) that utilizes Affymetrics gene expression data collected from 
1,881 breast cancer patients with associated stage, grade, nodal status and 
intrinsic molecular classification based on the paradigm first reported by 
the Perou Laboratory (Perou et al. 2000). All the above mentioned data are 
consistent with our findings that HRG expression is significantly increased 
in breast cancer and it is highly related to its progression.  The role of HRG 
as an emerging prognostic tumor marker for breast cancer detection has 
been studied and reported by other research groups which reported that 
HRG induces progression of breast cancer cells (Simantov et al. 2001, Jones 
et al. 2005, Place et al. 2011, Rivas et al. 2012). In most of these studies, 
the authors have shown that HRG can modulate angiogenesis, the latter is 
a central step in the transition of benign tumors to malignant one. They 
also mentioned that HRG promote angiogenesis in breast cancer. 
Furthermore, in a PhD dissertation (Jones 2009) the author used proteomic 
mass spectrometry approaches for identifying and discovery of new 
biomarkers for breast cancer. The author stated that there is directly 
proportional relation between the HRG protein and the breast cancer 
especially in late stage (stage 4) breast cancer and obese patients.  
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 Our primary focus was targeted on the evaluation of nano-
molecular assays to validate the tissue expression of HRG RNA as a potential 
biomarker for breast cancer prognosis. Moreover, it is hoped that 
incorporation of nano-molecular diagnostics into the routine management 
of breast cancer patients will result in better disease classification, as well as 
assistance in discovery of targeted treatment. Such objectives are more 
likely to bring us to our ultimate goal, which is the personalized management 
of breast cancer.  
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Table 2:  Sensitivity, Specificity, PPV, NPV & Accuracy of the assays used for breast tissue 
HRG RNA detection in different grades, stages and subtypes of Breast cancer. PPV: 
Positive Predictive Value, NPV: Negative Predictive Value, MNP: Magnetic Nanoparticles, 
AuNPs: Gold nanoparticles   
Parameter Sensitivity Specificity PPV NPV Accuracy 
Breast cancer (n=60) 
RT-PCR before  MNP  purification 71.7% 93.33% 95.56
% 
62.22
% 
78.89% 
RT-PCR after  MNP purification 80% 93.33% 92.3% 72.7% 86.67% 
AuNPs assay 90% 90% 94.7% 82.5% 91.11% 
Early stage (0+  I  ) (n=26) 
RT-PCR before  MNP  purification 84.6% 93.33% 84.6% 93.33
% 
90.7% 
RT-PCR after  MNP purification 88.5% 93.33% 85% 94.9% 91.86% 
AuNPs assay 92.3% 90% 80% 96.4% 90.7% 
 stage 2 (n=28) 
RT-PCR before  MNP purification 75% 93.3% 91.3% 80% 84.5% 
RT-PCR after  MNP purification 78.6% 93.3% 91.3% 90.3% 90.7% 
AuNPs  assay 85.7% 90% 88.9% 87% 87.9% 
stage 3 (n=6) 
RT-PCR before  MNP purification 33.3% 93.3% 50% 87.5% 83.3% 
RT-PCR after  MNP purification 50% 93.3% 60% 90.3% 86% 
AuNPs assay 100% 90% 66.7% 100% 91.7% 
Grade 1 (n=12) 
RT-PCR before  MNP purification 83.3% 93.33% 71.4% 96.6% 91.67% 
RT-PCR  after  MNP purification 91.6% 93.33% 73.3% 98.2% 93% 
AuNPs assay 91.67% 90% 64.7% 98% 90.2% 
Grade 2  (n=38) 
RT-PCR before  MNP purification 68.4% 93.3% 92.8% 70% 79.4% 
RT-PCR  after  MNP purification 76.3% 93.3% 93.5% 75.5% 83.3% 
AuNPs assay 86.8% 90% 91.7% 84.3% 88.2% 
Grade 3 (n=10) 
RT-PCR before  MNP purification 70% 93.3% 77.7% 90.3% 87.5% 
RT-PCR  after  MNP purification 80% 93.3% 80% 93.3% 90% 
AuNPs assay 100% 90% 76.9% 100% 92.5% 
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In conclusion, we propose to use an unmodified AuNPs-based assay 
for the direct detection of unamplified HURP RNA in clinical urine samples 
and unamplified HRG RNA in breast tissue samples for the early diagnosis 
and prognosis of urinary bladder and breast cancers respectively. Both 
assays are sensitive, specific, simple, rapid, detect the target RNA in early-
stage tumors and inexpensive. Moreover, we have introduced a magnetic 
nanoparticles purification step to increase the purity of the target RNA that 
will be used in downstream applications, such as the AuNPs assay or RT-PCR. 
Similar platforms could be developed for the detection of other cancer 
biomarkers, thereby making cancer diagnosis and screening of high-risk 
individuals more affordable and accessible to large patient populations. 
Subtype: Luminal A (n=27) 
RT-PCR before  MNP  purification 81.5% 93.3% 91.7% 84.8% 87.7% 
RT-PCR  after  MNP purification 88.9% 93.3% 92.3% 90.3% 91.2% 
 AuNPs assay 88.9% 90% 88.9% 90% 89.4% 
Subtype: Luminal B (n=11) 
RT-PCR before  MNP  purification 45.5% 93.3% 71.4% 82.3% 80.5% 
RT-PCR  after MNP purification 45.5% 93.3% 71.4% 82.3% 80.5% 
AuNPs assay 81.8% 90% 75% 93% 87.8% 
Subtype: Triple negative (n=15) 
RT-PCR before  MNP purification 80% 93.3% 85.7% 90.3% 88.9% 
RT-PCR  after MNP purification 93.3% 93.3% 87.5% 96.6% 93.3% 
AuNPs assay 100% 90% 83.3% 100% 93.3% 
Subtype: Her-2 overexpression (n=7) 
RT-PCR before MNP purification 71.4% 93.3% 71.4% 93.3% 89.2% 
RT-PCR after MNP purification 71.4% 93.3% 71.4% 93.3% 89.2% 
 AuNPs assay 85.7% 90% 66.7% 96.4% 89.2% 
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5 Dissertation Discussion
The focus of this thesis was the development of novel techniques for 
the direct detection of unamplified nucleic acids in clinical specimens using 
nanoparticles. Gold and magnetic nanoparticles were the main 
nanoparticles used in our studies. It is obvious that the introduction of 
AuNPs and magnetic nanoparticles for the direct purification & detection 
unamplified of nucleic acids directly from clinical samples will dramatically 
enhance the detection parameters such as: speed (lower time), high 
sensitivity, high specificity, simplicity and the most important the total cost 
of the assay. Several methods have been developed for the detection of 
nucleic acids using AuNPs by many groups. Despite, the high sensitivity and 
specificity of these detection methods, more work still needs to be applied 
to real clinical specimens. In this thesis, our main focus was taking the 
advantages of AuNPs in nucleic acid detections, and magnetic nanoparticles 
for nucleic acids purification from the samples. We have used the 
unmodified negatively charged and positively AuNPs method for the 
development of colorimetric assays. The developed assays have been 
applied to detect of HCV RNA directly from serum samples, the detection of 
HURP RNA from urine samples as a urinary bladder cancer biomarker and 
finally for the detection of HRG RNA in tissues as a prognostic biomarker for 
breast cancer. The assays we developed have been optimized and compared 
to the currently used methods for the targets detection and promising 
results have been obtained. 
Unmodified AuNPs in HCV RNA detection in serum 
samples 
Unmodified AuNPs detection of nucleic acids was first developed (Li 
et al. 2004a, Li et al. 2004b). It is based on the adsorption of the small single 
stranded DNA (ssDNA) onto the negatively charged AuNPs that in turn 
increases their negative charge to prevent salt induced aggregation, while 
double stranded DNA (ds DNA) doesn't adsorb onto the AuNPs surface 
because the repulsion between their negatively charged phosphate 
backbone and the negatively charged AuNPs. When AuNPs are added to a 
saline solution containing the target nucleic acid and its complementary 
unlabeled oligotargeter (ss DNA), aggregation of AuNPs occurs and their 
color changes from red to blue, because the oligotargeter is not free to be 
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adsorbed onto the AuNPs surface to stabilize the nanoparticles against 
aggregation induced by the saline in the solution. On the other hand, in the 
absence of the target, the oligotargeter is free to stabilize the AuNPs 
colloidal solution against salt induced aggregation and the solution color 
remains red. In our study, we have used this principle for the development 
of a colorimetric assay for the direct detection of HCV RNA extracted from 
clinical serum samples. The main problem that we faced in developing this 
assay was working on serum samples of HCV infected patients. The serum 
may contain some cell free DNA which are small fragments of DNA, in 
addition to nucleoproteins (Sisco 2001). These short fragments of nucleic 
acids may interfere with the assay and stabilize the free AuNPs leading to 
false negative outcome. Therefore, many available commercial kits have 
been tried for HCV RNA extraction from serum, and we conclude that any 
available commercial extraction kit for total RNA purification can be used, 
but that it should employed with a DNase step to remove the DNA molecules 
that could be in the final elution to prevent the generation of false negative 
results. The assay components are: AuNPs, the oligotargeter (ssDNA specific 
to HCV RNA), a sodium chloride solution, and the viral RNA (target). The first 
3 components should be adequately optimized regarding their 
concentrations and/or amount, for example: if the concentration of the 
oligotargeter is very high and the target concentration is low, there will be 
enough oligotargeter in the solution to be adsorbed onto the AuNPs and 
prevent the aggregation and false results obtained, after hybridization of the 
oligotargeter with its complementary HCV RNA and vice versa. 
Consequently, the assay was performed by adding hybridization buffer 
(oligotargeter and sodium chloride with final concentrations of 1 M & 
0.08M respectively) to the sample, followed by AuNPs to a final 
concentration of 10 nM and the color change was observed within 2 
minutes. The assay has a sensitivity and specificity of 92% & 88.9% 
respectively, and a detection limit of 50 RNA copies/reaction. The proposed 
assay has many advantages as: (i) there is no need for RNA amplification. (ii) 
It is suitable for tracking an active infection even at low viral titers; (iii) It has 
acceptable sensitivity and specificity and, (iv) a short turnaround time (v) It 
cost-effective as no expensive equipment is needed for the detection. The 
sensitivity and specificity could be improved by enhancing the purity of the 
extracted RNA by applying for example a specific capture of HCV RNA using 
magnetic nanoparticles. Also, it could be developed to be a quantitative test 
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by adding spectrophotmetric quantification of the color outcome against a 
standard curve. Moreover, the assay could be easily optimized to detect 
SNPs in the HCV RNA, by proper selection of the oligotargeter and its 
annealing temperature. This will be essential when applied onto HCV 
genotyping which depends mainly on the detection of SNPs within the viral 
RNA. To our knowledge, this is the first study done using unmodified AuNPs 
for the direct detection of unamplified HCV RNA from serum samples, and 
upon fine tuning and optimization, it may be competitive with the available 
Hepatitis C Virus commercials immuno-assays and the RT-PCR methods. 
Moreover, it could be used in HCV screening especially in the early (acute) 
infection phase where the immuno-assays are inadequate, as it takes about 
70 days for the HCV antibodies to appear in the blood, while the HCV RNA is 
detected in the serum within 21 days (Moller et al. 2003, Yoshizawa 2004, 
Fabris et al. 2008). 
Cationic AuNPs in detection of HCV in serum 
samples 
Cationic AuNPs have been used for diagnostic molecular assays, for 
example a microarray assay (solid support) for gene expression analysis 
using positively charged AuNPs (Sun et al. 2005). A colorimetric assay has 
also been developed for the detection of HIV in clinical samples using 
cationic gold nanorods and label free probe DNA (He et al. 2008). In chapter 
3, we report the use of cationic gold nanoparticles for the detection of HCV 
RNA extracted from clinical serum samples. To increase the specificity of the 
assay, we have utilized a specific HCV RNA extraction using homemade 
magnetic nanoparticles functionalized with HCV RNA specific 
oligonucleotide. The assay is based on adding cationic AuNPs onto the 
sample, in the presence of phosphate buffer. In the presence of the target 
nucleic acid, the cationic AuNPs were aligned onto the negatively charged 
phosphate backbone of the target nucleic acid, the presence of phosphate 
buffer increases the aggregation of the cationic AuNPs in the case of positive 
samples only, where the phosphate ions bind to the AuNPs aligned onto the 
target RNA, then another row of AuNPs attached to the phosphate ions and 
then aligned to another RNA molecule and so on, until several layers of 
(RNA/AuNPs/phosphate ions/AuNPs/second RNA), and aggregation occurs 
changing the colloidal solution of AuNPs from red to blue. On the other hand, 
in the absence of any nucleic acid in the sample, the AuNPs are far from each 
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other and in the same time the amount of phosphate ions in the solution is 
insufficient for the nanoparticles to aggregate. To our knowledge, we were 
the first to propose and use cationic AuNPs in direct detection of unamplified 
RNA from serum clinical samples. The scanning electron microscope images 
obtained confirmed the principle we proposed. The introduction of a specific 
magnetic nanoparticles based extraction step prior to the assay increases 
the purity of the sample and ensures the presence of only the HCV RNA 
target in the sample. The assay could be utilized for the detection of any 
nucleic acid target, after specific extraction of the target nucleic acid. In 
conclusion, we report for the first time the development of colorimetric 
solution based assay using cationic nanoparticles for the direct detection of 
HCV RNA from clinical samples, the assay has sensitivity and specificity more 
than 95%, and a detection limit of 15 IU/ml. Moreover, the color obtained in 
the assay is very stable and does not change. It could be improved easily to 
become a quantitative assay for viral load measurements. Moreover the 
turnaround time of the assay including the RNA extraction is about 75 
minutes, which is almost one third the time needed by standard Real time 
RT-PCR, and the cost of the assay does not exceed US$10. The assay could 
be easily modified to be fully automated and can be used in routine 
screening and/or diagnosis of HCV RNA or any other nucleic acid target in 
solution after proper extraction. 
Unmodified AuNPs in tumor marker detection 
A major clinical need in cancer research is the development of non-
invasive, simple, sensitive, specific and cheap methods for the early 
diagnosis and prognosis of tumors. Moreover, identifying novel biomarkers 
is a quickly growing field due to the accumulation of information from many 
disciplines as epigenetics, proteomics, transcriptomics, and genomics 
leading to the discovery of novel potential biomarkers for different tumors. 
We have tried the unmodified AuNPs assay on two emerging biomarkers: 
the first was Hepatoma Up Regulated Protein (HURP) RNA in urine samples 
for urinary bladder cancer diagnosis, and the second was Histidine-Rich 
Glycoprotein (HRG) in breast tissue for breast cancer prognosis. In these two 
independent studies, each biomarker RNA was extracted from clinical 
specimens, and then purified by our homemade magnetic nanoparticles for 
obtaining pure target. Then, the unmodified AuNPs assay was optimized and 
the results obtained were compared to the conventional RT-PCR method 
Dissertation Discussion 
Page 100 
and the standard methods used in tumors detection. For the detection of 
HURP RNA as a novel biomarker for urinary bladder cancer diagnosis, the 
urine samples were collected from patients, benign and normal individuals.  
The developed colorimetric assay has a sensitivity and specificity of 88.5% 
and94% respectively, with a detection limit of 2.5 nmol/L.  RT-PCR was done 
for all the samples before and after magnetic extraction step, the sensitivity 
of RT-PCR was increased from 64% to 84%. Upon combining, the nano assay 
with urine cytology improved the sensitivity of the standard cytology 
method, from 62% to 100%. Thus a colorimetric AuNPs based assay has been 
developed for the direct detection of HURP RNA in urine samples for the 
diagnosis of urinary bladder cancer even in the low grade and superficial 
bladder cancer. The assay is sensitive, specific, rapid and cost effective and 
non-invasive and could be developed easily for detecting SNPs by proper 
optimization of the oligotargeter-target annealing conditions. On the other 
hand, HRG RNA was detected in breast tissues from malignant, benign and 
normal individuals. The developed assay has a sensitivity and specificity of 
90%, with a detection limit of 1.5 nmol/L.  RT-PCR was done for all the 
samples before and after the magnetic extraction step. The RT-PCR 
sensitivity increased from 71.1% to 80 %. Also, the sensitivity of the assay 
was 92.3% at the early stage cancer cases, while it was 84.6% using the 
conventional RT-PCR method. Herein, we are proposing a novel colorimetric 
assay for the detection of HRG RNA in breast tissues for prognosis and early 
diagnosis of breast cancer. In conclusion, Current molecular diagnostic 
methods have come a long way towards better, faster, cost-effective and 
reliable assays. Nevertheless, most are still time consuming and require 
expensive equipment (e.g. Real-time PCR, DNA sequencing), and/or 
reagents (e.g. fluorescent dyes, DNA polymerases), highly specialized 
laboratories and highly trained personnel. In the end, all these factors 
restrict their use at the point of care (POC) or in a larger number of 
laboratories, especially in countries with fewer resources available to 
healthcare. Developing novel assays based on nanoparticles will allow 
decreasing the costs associated with genetic tests with higher sensitivity and 
specificity, thus making them available to a broader population worldwide.  
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7 Summary 
Advances in molecular diagnostic technologies have led to substantial 
progress in the understanding and detection of a multitude of diseases including 
infectious, genetic diseases and cancer. These technologies have become a 
cornerstone in modern clinical diagnostics, and can be broadly classified into either 
nucleic acid amplification techniques (NAT) or signal amplification techniques, or 
direct detection using a labeled probes (e.g. using a fluorescent dye or a 
radioisotope). These molecular detection strategies have the advantage of being 
sensitive and specific; however, they are all relatively costly, labor-intensive, and 
require a sophisticated laboratory infrastructure. Moreover amplification based 
assays suffer from the risk of amplicon cross- contamination.  There, is therefore a 
need to develop simpler and more cost-effective molecular diagnostic assays for 
the direct purification and detection of unamplified nucleic acids in clinical samples 
with acceptable sensitivity and specificity, short turnaround time, and suitable for 
low resource settings. This is particularly true for the poorer countries with less 
developed health care systems.   
Nanotechnology is a powerful and rapidly evolving field whose integration 
into the molecular diagnostics arena would have a positive impact on the 
development of simpler effective nucleic acid testing. The utilization of nanoparticles 
would also allow assay miniaturization development of “at point of care” assays. One 
of the most promising nano-structures are gold nanoparticles (AuNPs) which exhibit 
a unique phenomenon known as Surface Plasmon Resonance (SPR) that is 
responsible for their characteristic optical properties such as large molar extinction 
coefficients. Due to SPR, AuNPs in colloidal solution have an intense red color which 
changes to blue upon aggregation of the AuNPs. Both positively and negatively 
charged AuNPs exhibit their unique optical properties and have been utilized in the 
development of simple, sensitive, specific, rapid and cheap colorimetric assays for 
nucleic acids detection that can compete with the currently used molecular assays. 
Another type of nanoparticles that is demonstrating high potential for utility in 
molecular assays is iron oxide magnetic nanoparticles (MNPs). These nanoparticles 
are characterized by Superparamagnetic properties, and with proper 
functionalization, can be used for the selective and efficient capture of the target 
bio-molecule. The combined use of MNPs with other signal-generating nanoparticles 
would allow the highly sensitive and accurate detection of target nucleic acids in 
clinical samples.  
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Here we have developed two applications for direct detection of unamplified 
nucleic acids in clinical samples. One application was the direct detection of 
unamplified Hepatitis C Virus (HCV) RNA. This was done using two approaches; the 
first employed negatively charged unmodified AuNPs and the other a combination 
of MNPs for RNA capture, and cationic AuNPs for detection. Both approaches were 
tested on clinical serum samples from HCV infected patients. The second application 
was the detection of cancer biomarkers. We combined MNPs specific capture with 
unmodified citrate AuNPs for detection of two novel biomarkers. One biomarker, 
Hepatoma Up Regulated Protein (HURP) RNA, was detected in clinical urine samples 
from urinary bladder cancer patients. The other target was the RNA for the breast 
cancer biomarker, Histidine-Rich Glycoprotein (HRG), which was detected in breast 
tissue. 
In chapter 2: An assay prototype using AuNPs unmodified was developed for 
the direct detection of HCV RNA extracted from clinical serum sample. The results 
obtained are comparable to the currently used standard detection method; real 
Time RT-PCR. The novel assay has a sensitivity and specificity of 92% and 89.9% 
respectively, with a detection limit of 50 copies/reaction. The assay is simple, rapid, 
sensitive and specific and requires no detection equipment. Moreover, it could be 
further developed to be quantitative using a spectrophotometer. 
In chapter 3: In this chapter, we present a prototype for a homogenous 
solution based assay (not solid based assay) for the detection of unamplified nucleic 
acid detection using cationic AuNPs, which align onto the negatively charged 
phosphate backbone of the long nucleic acid resulting to a change in color from red 
to blue. To increase the specificity of this assay, in-house MNPs functionalized with 
HCV specific oligonucleotides were prepared to selectively capture the viral RNA 
after total RNA extraction. The assay prototype has a sensitivity and specificity of 
96.5% and 96% respectively, with a detection limit of 15IU/ml blood (1 IU 
corresponds to 2-5 copies). In addition to its simplicity, cost effectiveness, and its 
short turn-around time (75 min), this assay is amenable to automation 
In chapter 4: Negatively charged unmodified AuNPs were employed for the 
detection of selected tumor biomarkers. The first was HURP RNA in urine which is an 
emerging biomarker for the early detection of urinary bladder carcinoma. The 
second is a novel biomarker of breast cancer; HRG RNA, in breast tissue. We have 
used magnetic nanoparticles conjugated to an oligonucleotide specific to the 
respective marker’s RNA to selectively capture it and enhance the sample purity. This 
was followed by detection using the same concept of the previously described assay 
using negatively charged AuNPs. The sensitivity and specificity of HURP AuNPs 
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developed assay were 90% & 94% respectively, while that of the HRG was 90% for 
both sensitivity and specificity. 
 Moreover, incorporation of a MNP purification step with conventional RT-
PCR has improved the HURP RT-PCR sensitivity from 64% to 84%, and the specificity 
from 90 to 94% while the sensitivity for the HRG RT-PCR has been improved from 
71.7% to 80%. The magnetic purification step improved the unmodified citrate 
AuNPs assay on both HURP RNA and HRG RNA. Thus, the use of magnetic 
nanoparticles in the target purification has generated assays (unmodified AuNPs, 
and RT-PCR) with a high specificity and sensitivity. 
In summary the assay prototypes described in this work illustrate the 
effectiveness and versatility of diagnostic platforms using different AuNPs and 
MNPs. The nanoparticles based assay platforms have high potential for the detection 
of high burden infections as well as cancers. These assays could aid in complex 
disease management due to their low cost, simplicity and short turnaround time. 
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8 Samenvatting 
De vooruitgang in moleculair diagnostische technieken hebben gezorgd voor 
een aanzienlijke verbetering in het begrijpen en detecteren van vele ziekten, infectie 
ziektes, genetische ziektes en kanker. Deze technologie heeft zich ontwikkeld tot een 
hoeksteen van moderne klinische diagnostiek en kan ruwweg worden 
onderverdeeld in nucleïnezuuramplificatie technieken (NAT) of signaal amplificatie 
technieken of rechtstreekse detectie gebruikmakend van probes (bijv. d.m.v. 
fluorescentie of radioactiviteit). 
Moleculaire detectie technieken hebben het voordeel dat ze selectief en 
specifiek zijn, echter ze zijn vrij duur, arbeidsintensief, en hebben een geavanceerde 
laboratorium infrastructuur nodig. Verder lopen amplificatie technieken het gevaar 
van amplicon kruis-contaminatie. Het is daarom noodzakelijk een eenvoudige en 
goedkope diagnostische methodes te ontwikkelen om niet geamplificeerde 
nucleïnezuren in klinische samples met een goede specificiteit en gevoeligheid in 
korte tijd te detecteren in een eenvoudige omgeving.  
Nanotechnologie is een krachtig en snel ontwikkelend veld, waarvan de 
integratie in het moleculair diagnostisch veld een positieve invloed zou hebben op 
de ontwikkeling van effectieve testen voor de detective van nucleïnezuren. Daarbij 
komt dat het gebruik van nanopartikels een miniaturisatie mogelijk zou kunnen 
maken van “op de [lek van zorg” metingen. Een van de veel belovende 
nanostructuren zijn goud nanopartikels (AuNPs) die de unieke eigenschap Surface 
Plasmon Resonantie (SPR) hebben die verantwoordelijk is voor de karakteristieke 
optische eigenschappen zoals een hoge extinctie coëfficiënt. Vanwege SPR hebben 
AuNPs een intens rode kleur in een colloïdale oplossing die veranderd naar blauw als 
de AuNPs aggregeren. Zowel positief als negatief geladen AuNPs hebben hun unieke 
optische eigenschappen en zijn gebruikt om een eenvoudige, gevoelige, specifieke, 
snelle en goedkope kleur detectie te ontwikkelen van nucleïnezuren, die de huidige 
moleculaire detectie methodes kan vervangen. Een ander soort nanopartikel dat 
groot potentieel heeft voor moleculaire diagnostiek zijn ijzer oxide magnetische 
partikels (MNPs). Deze nanopartikels worden gekarakteriseerd door 
superparamagnetische eigenschappen, die met de juiste functionele groepen, 
gebruikt kunnen worden voor de selectieve en efficiënte binding van het te 
detecteren bio-molecuul. Het gecombineerde gebruik van MNPs met andere signaal 
afgevende nanopartikels zou een zeer gevoelige en nauwkeurige meting toestaan 
van de te meten nucleïnezuren in klinische monsters. 
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Wij hebben twee methodes ontwikkeld voor de detectie van niet 
geamplificeerde nucleïnezuren in klinische monsters. De eerste methode is de 
directe detectie van niet geamplificeerd Hepatitis C virus (HCV) RNA. Dit is gedaan 
door middel van twee benaderingen; één omhelst negatief geladen niet 
gemodificeerdeAuNPs, de ander een combinatie van MNPs voor de binding van RNA 
en cationische AuNPs voor de detectie van het RNA. Beide benaderingen zijn getest 
op klinische samples van patienten geinfecteerd met HCV. De tweede toepassing 
was het detecteren van kanker biomarkers. Een biomarker die werd gedetecteerd in 
klinische urine monsters was het RNA voor de blaaskanker marker Hepatoma Up 
Regulated protein (HURP). De ander marker was een borsttumor marker Histidine 
Rich Glycoprotein (HRG) in borstweefsel. 
Hoofdstuk 2 beschrijft de ontwikkeling van een protoytype assay met niet 
gemodificeerde AuNPs voor de detectie van HCV RNA geëxtraheerd uit serum uit de 
kliniek. De resultaten zijn vergelijkbaar met de huidige standaard detectie methode, 
real time RT-PCR. De nieuwe methode heeft een gevoeligheid van 92% en een 
specificiteit van 89,9% met een detectielimiet van 50 kopieën per reactie. De 
methode is eenvoudig, snel, gevoelig en specifiek en heeft geen meetapparatuur 
nodig. De methode zou verder kunnen worden ontwikkeld tot een kwantitatieve 
methode door het gebruik van spectrofotometrie. 
Hoodfstuk 3 beschrijft een prototype methode om niet geamplificeerd 
nucleïnezuur te meten met AuNPs, die zich rangschikken op de negatief geladen 
fosfaatketen van het nucleïne zuur, hetgeen resulteert in een verandering van kleur 
van rood naar blauw. Om de specificiteit van de methode te verhogen zijn zelf 
gemaakte MNPs gefunctionaliseerd met HCV specifieke oligonucleotiden om 
selectief het virale RNA af te vangen na een extractie van het totale RNA. Het 
prototype heeft een gevoeligheid van 96,5% en een specificiteit van 96% met een 
detectie limiet van 15 IU/ml bloed (1 IU komt overeen met 2-5 kopieën). Vanwege 
zijn eenvoud, geringe kosten en snelle doorlooptijd (75 min.) is de methode geschikt 
voor automatisering.  
Hoofdstuk 4 beschrijft het gebruik van negatief geladen ongemodificeerde 
AUNPs voor de detectie van specifieke kankermerkers. De eerste was HURP RNA in 
urine hetgeen een in opgang zijnde biomarker is voor de vroege detectie van een 
blaascarcinoom. De tweede is een nieuwe biomarker in borstkanker, HRG RNA. We 
hebben gebruik gemaakt van nanopartikels die geconjugeerd zijn aan een 
oligonucleotide die specifiek is voor het merker RNA om dat RNA af te vangen en de 
zuiverheid van het te meten monster te verhogen. Vervolgens wordt hetzelfde 
concept gebruikt voor detectie als hierboven beschreven voor negatief geladen 
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AuNPs. De gevoeligheid en specificiteit van de HURP AUNPs waren respectievelijk 
90% en 94%, terwijl die van HRG AuNPs beiden 90% waren. 
Daarbij komt dat het inbouwen van een MNP zuiveringsstap met 
conventionele PCR de HURP RT-PCR gevoeligheid verbeterd heeft van 64% naar 84% 
en de specificiteit van 90 naar 94%, terwijl die van HRG RT-PCR verbeterd is van 71,75 
naar 80%. Bovendien is de detectie van HURP en HRG RNA verbeterd door de 
magnetische zuiveringsstap voor de meting met niet gemodificeerde AuNPs. Dus het 
gebruik van magnetische nanopartikels in een zuiveringsstap heeft een methode 
(ongemodificeerde AuNPs en RT-PCR) opgeleverd met een hoge specificiteit en 
gevoeligheid. 
In conclusie, de hier beschreven prototype assays illustreren de effectiviteit 
en veelzijdigheid van diagnostische methodes, die gebruik maken van verschillende 
AuNPs en MNPs. De op nanopartikels gebaseerde methodes hebben potentieel een 
hoge waarde voor de detectie van infectie ziektes en kanker. De hier ontwikkelde 
methodes zouden kunnen helpen in de management van complexe ziektes 
vanwege hun lage kosten, eenvoud en snelle doorlooptijd.
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